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ABSTRACT 
VITAMIN D LEVELS AND RISK OF DYSLIPIDEMIA AMONG US CHILDREN 
WITH DIABETES AND OBESITY. 
MAY 2011 
ELSINA E. HAGAN, B.SC. (HONS), UNIVERSITY OF GHANA, LEGON 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Lisa Chasan-Taber (ScD) 
Dyslipidemia is increasing among U.S. children, and the prevalence is highest 
among children with diabetes and obesity. Recently, vitamin D deficiency has been 
suggested as a possible dietary risk factor for dyslipidemia. Despite the high prevalence 
of vitamin D deficiency amongst children, virtually no studies have evaluated the 
association between vitamin D and dyslipidemia among children. We evaluated the 
vitamin D and dyslipidemia relationship among 240 children and adolescents aged 2 
through 21 years who were outpatients of a pediatric endocrinology unit at a large tertiary 
care facility in Western Massachusetts from April 2008 to April 2010. Eligible children 
were those with either obesity and/or type 1 or 2 diabetes mellitus. A total of 17.4% of 
children had severe (<15.0 ng/ml) vitamin D deficiency, 19.2% had moderate (15.0-19.9 
ng/ml) deficiency, 36.3% were insufficient (20.0-29.9 ng/ml), and 27.1% had normal 
(≥30.0 ng/ml) levels. A total of 28.8% of children had high total cholesterol (TC ≥180 
mg/dL), 19.6% had high triglycerides (TG; <10years: ≥110 mg/dL, ≥10years: ≥130 
mg/dL), 21.3% had low high density lipoprotein (HDL <40 mg/dL), and 6.7% had high 
low density lipoprotein (LDL ≥130 mg/dL). Moderate vitamin D deficiency was 
associated with increased risk of high TC (adjusted odds ratio [OR adj] = 2.9, 95% 
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confidence interval (CI): 1.0, 8.8) compared to children with normal vitamin D levels. 
Severe vitamin D deficiency was associated with an increased risk of low HDL (OR adj = 
3.5, 95% CI: 1.0-12.3) and high TG (OR adj = 11.7, 95% CI: 1.9, 70.3) compared to 
children with normal vitamin D levels. Children with moderate vitamin D deficiency had 
approximately 3-fold increased risk of high TC compared to children with normal 
vitamin D levels. In comparison to children with normal vitamin D levels, severe vitamin 
D deficiency was associated with a strong and significant increased risk of low HDL and 
high TG; with a significant dose-response relationship. Additionally, in linear regression 
analyses, we found that an increase in vitamin D deficiency was associated with a 
significant mean increase in all four measures of dyslipidemia. Vitamin D adequacy may 
reduce the risk of dyslipidemia in children. 
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CHAPTER I 
INTRODUCTION 
Dyslipidemia is a metabolic disorder of lipoprotein metabolism which results in 
abnormal excesses of: total cholesterol (TC), low-density lipoprotein cholesterol (LDL-
C), or triglycerides, or a deficiency in high-density lipoprotein cholesterol (HDL-C) (1). 
Approximately 10% of US children are affected by hyperlipidemia; a type of 
dyslipidemia characterized by elevated levels of blood lipids (2, 3). Dyslipidemia is one 
of the key factors considered by the National Cholesterol Education Program Adult 
Treatment Panel (NCEP - ATP III) in defining metabolic syndrome. The US prevalence 
of metabolic syndrome in adults ≥ 20 years is 20% (3). In US adolescents ≤ 20 years, 
6.4% can be classified as having metabolic syndrome based on age modified NCEP - 
ATP III criteria, out of which 50% are severely obese children and adolescents (3). 
Childhood dyslipidemia is associated with the risk of developing CVD in 
adulthood (4). Familial hypercholesterolemia (FH), familial combined hyperlipidemia 
(FCHL), familial hyperglyceridemia and hyper-apoprotein – B, are some commonly 
inherited lipoprotein disorders observed in children of parents with premature 
cardiovascular disease (CVD) which makes these youth at high risk of developing CVD 
in the future (1, 2, 5). 
 The primary known risk factors for dyslipidemia include genetic disorders of lipid 
metabolism such as familial hypercholesterolemia. However secondary causes of 
dyslipidemia in adolescents are diabetes, cigarette smoking and anorexia nervosa. In view 
of the rising trends in dyslipidemia in children and adolescents, there is the need to 
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continually identify new risk factors for dyslipidemia in this population. Vitamin D 
deficiency is thought to be one of the newer risk factors for dyslipidemia in children and 
adolescents, especially for those with other underlying metabolic syndromes.  
Vitamin D deficiency, mainly in the form of rickets, became epidemic in the US 
at the end of the 19th century. In children and adolescents, extreme cases of vitamin D 
deficiency result in rickets and, in adults it leads to osteomalacia. However, in recent 
years, there has been increasing interest in the association between vitamin D deficiency 
and diseases, such as cardiovascular disease (CVD) (6). There is substantial evidence 
suggesting that hypovitaminosis D (low levels of vitamin D) influences the development 
of CVD after age 50 (6). In vitamin D deficient youths, successful repletion of vitamin D 
has been shown to reduce the possibility of developing CVD in adulthood (6). Because 
pathological evidence suggests that precursors of CVD start from childhood (6), these 
findings support evaluating the association of vitamin D deficiency with CVD risk factors 
(6). 
 However, to date no study has evaluated the relationship of vitamin D deficiency 
with dyslipidemia, especially in children with obesity and / or diabetes. Therefore, we 
evaluated the association between vitamin D deficiency and blood lipids among children 
and adolescents, 2 through 21 years old, diagnosed with either diabetes and/or obesity. 
Specifically our aims were to evaluate the association between vitamin D deficiency and 
high density lipoprotein (HDL), low density lipoprotein (LDL), total cholesterol (TC) and 
triglycerides (TG), among these high risk children. We used a cross-sectional study 
design; data on serum 25(OH)Vitamin D levels as well as fasting (> 12 hours) blood lipid 
levels were obtained via laboratory analysis and chart review of medical record from the 
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Pediatric Endocrinology and Pediatric Weight Management Clinics, of the Baystate 
Medical Center’s Children’s Hospital in Springfield, Massachusetts. The American 
Academy of Pediatrics (AAP) and National Cholesterol Education Program (NCEP) 
guidelines, were used in classifying blood lipid levels. This study base represented an 
ethnically and socioeconomically diverse population of which majority were 
predominantly non-Hispanic white and Asian.  
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CHAPTER II 
LITERATURE REVIEW 
A. Biological Evidence (Physiology) of the Association between Vitamin D 
Levels and Dyslipidemia. 
Dietary sources of vitamin D include oily fish, irradiated mushrooms, dairy foods 
such as milk and eggs, whole grains and cereals as well as other fortified foods such as 
juices (7). However, the bulk (90%) of vitamin D utilized by humans is obtained through 
the synthesis of vitamin D in the skin through a sturdy photolytic procedure. This process 
involves the action of sunlight (exposure to ultraviolet (UVB) radiation 290-315nm from 
the sun) on a cholesterol derivative i.e. 7-dehydrocholesterol, present in the plasma 
membrane of epidermal keratinocytes and dermal fibroblasts. Once the energy from the 
sun has been absorbed by the double bonds in the “B ring” of the 7-dehydrocholesterol, 
previtamin D is produced, which next gradually converted from one isomer to the other 
(rearrangement of the double bonds and opening of the B rings) into vitamin D3 (7, 8). 
The natural form of vitamin D produced from this photosynthesis in the skin is vitamin 
D3, (this compound, 25-hydroxyvitamin D3 (25(OH)D3)), which in its present form is 
metabolically inert or inactive, needs to be modified into its functional form in the body. 
The form in which vitamin D is commonly monitored to assess vitamin D status of 
patients is 25-hydroxyvitamin D3 (25 (OH) D3)) (8).  
The exact mechanisms by which vitamin D deficiency influences dyslipidemia 
have not been fully elucidated (9). However, three indirect mechanisms have being 
suggested as possible ways in which vitamin D deficiency may influence blood lipid 
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metabolism or profiles. In terms of the first mechanism, Pittas et al. (2010), suggests a 
possible direct mechanism in which vitamin D deficiency may influence the risk of 
cardio-metabolic outcomes involving vitamin D receptor activation. This mechanism 
though, poorly understood in relation to the influence of vitamin D on dyslipidemia, is 
thought to be linked to how the vitamin D receptor influences other cardiometabolic 
outcomes such as hypertension (10). In terms of this mechanism, cardiac myocytes, 
endothelial, and smooth vascular muscle cells express both the vitamin D receptor and 
the 1-α-hydroxylase enzyme which then activates the inactive circulating vitamin D 
precursor (25(OH)D) into the active vitamin D metabolite and possibly increasing 
lipoprotein lipase enzyme levels and subsequently decreasing TG levels (10). 
A second possible mechanism suggests that vitamin D may decrease blood lipid 
levels, specifically TG plasma levels, via regulation of vitamin D adipocytes (10). This 
mechanism is as a result of the disruption of the mevalonate pathway (HMG-CoA 
reductase pathway), by the effects of statin drug therapy, which function as inhibitors of 
the 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme and 
subsequently causes an increase in 7-dehydrocholesterol (10, 11). The excess 7-
dehydrocholesterol in the human body is then converted to 25-hydroxycholecalciferol by 
the action of sunlight or the CYP11A1 enzyme (11). This action leads to an increase in 
vitamin D levels in the body and a corresponding decrease in TG levels possibly due to 
elevated levels of the lipoprotein lipase enzyme resulting from the disruption of the 
mevalonate pathway (10, 11). 
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The third proposed mechanism linking vitamin D deficiency with dyslipidemia, is 
via the elevation of peripheral insulin resistance in the body (11). This mechanism is also 
poorly understood.  
In summary three possible indirect mechanisms have been proposed linking 
vitamin D to dyslipidemia: the first involves the activation of the vitamin D receptor, the 
second is as a result of the disruption of the mevalonate pathway (HMG-CoA reductase 
pathway) as a result of statin drug therapy, and the third mechanism is as a result of the 
elevation of peripheral insulin resistance in the body. 
 
B. Epidemiology of Vitamin D Levels and Dyslipidemia (Abnormal Lipid 
Levels) 
To the best of our knowledge, over the past five years eleven epidemiological 
studies have evaluated the association between vitamin D and cardiovascular risk factors 
including dyslipidemia (6, 12-21), eight of which were US based (6, 12-15, 18, 19, 21) 
and 3 international ones (16, 17, 20).  
Out of the eight epidemiological studies conducted amongst older populations 
mainly ≥ 20 years, six were conducted cross-sectionally (12, 13, 16, 17, 19, 21), while 
only two (18, 20) prospectively evaluated the association between vitamin D deficiency 
and dyslipidemia. Two out of these eight studies in adults, found a negative association, 
(12, 21), another two found a positive association; (17, 18), while the remaining four; 
(13, 16, 19, 20) found null associations between dyslipidemia and vitamin D deficiency. 
 Despite immense recent interest in vitamin D deficiency and dyslipidemia in 
children and adolescents, only three out of the eleven epidemiologic studies investigated 
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this association in children and adolescents ≤ 20 years old; Kumar et al (2009), Reis et al 
(2009) and Ashraf et al (2009).  
Due to the conflicting or inconsistent epidemiological evidence and the limited 
number of epidemiological studies relevant to our population, we included findings from 
studies in these eight older populations (12, 13, 16-21) that evaluated vitamin D 
deficiency and dyslipidemia in our literature review. To the best of our knowledge, there 
are no previous studies evaluating the relationship between vitamin D deficiency and 
dyslipidemia, specifically looking at abnormal blood lipid (high density lipoproteins 
(HDL), low density lipoproteins (LDL), total cholesterol (TC) and triglycerides (TG)) 
levels, in children with diabetes and obesity who are at high risk of developing 
cardiovascular disease in the US. However a number of studies have focused on the 
association between vitamin D deficiency and dyslipidemia in older populations (e.g. 
people 20 years and older) (12, 13, 16-21). 
The first notable epidemiologic study of this association in children was a cross-
sectional study designed and conducted by Kumar et al (2009), in a nationally 
representative sample of 6275 US children aged 1 to 21 years, in the National Health and 
Nutrition Examination Survey in 2001 to 2004. The Diasorin assay was used in assessing 
the serum vitamin D levels. Study subjects were categorized into three groups based on 
these vitamin D status: vitamin D deficient (< 15 ng/mL), and vitamin D insufficiency 
(15-29 ng/mL), vitamin D sufficiency (>30 ng/mL) (15, 22). Vitamin D supplement use 
was also accessed via self reported questionnaire and pill bottle review. Serum HDL and 
TC were assessed using the Beckman Synchron LX20 assay. Children with diabetes were 
eligible for the study if they met all other requirements.  
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In a multivariable-adjusted analysis children and adolescents, with vitamin D 
insufficiency or deficiency were more likely to have lower levels of high-density 
lipoprotein cholesterol (HDL-C) lipid levels in comparison to children with sufficient or 
normal vitamin D levels (difference: -2.29 mg/dL (95% CI -3.57 to -1.01) , p = 0.001) 
and (difference: -3.03 mg/dL (95% CI -5.02 to -1.04) , p = 0.004) respectively (15). 
Similarly total cholesterol was higher among vitamin D sufficient children compared to 
vitamin D insufficient; (difference: -3.66 mg/dL (95% CI -7.09 to -0.23) , p = 0.04) in a 
multivariable adjusted analysis (15). Hence this implied that vitamin D insufficiency and 
deficiency, was statistically significantly associated with lower levels of high density 
lipoprotein, additionally vitamin D insufficiency was also significantly associated with 
lower levels of total cholesterol in children and adolescents. After excluding all obese 
children from their analysis, as a means of controlling for residual confounding, the 
observed relationships between vitamin D insufficiency and deficiency with both TC and 
HDL levels were similar to that described previously for the entire study sample. This 
implied that irrespective of a child or adolescent’s adiposity (being obese or non obese), 
vitamin D insufficiency and deficiency were significantly associated with low levels of 
HDL, whiles vitamin D insufficiency was also significantly associated with low levels of 
TC. 
This study was limited by the lack of information on the seasons in which the 
vitamin D measures were taken. This is relevant because vitamin D levels vary greatly 
with sunlight exposure. In addition the measures obtained for 25(OH)D levels, may have 
been higher than the average 25(OH)D levels in the population, because screening and 
enrollment of participants from the northern states in the NHANES study occurred during 
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the summer. Finally, this study did not assess TG and LDL but only focused on HDL and 
TC which may limit its generalizability to adolescents whose dyslipidemia is as a result 
of an abnormality in the levels of LDL and TG.  
In the second of the three studies conducted among children and adolescent 
populations to evaluate the association between vitamin D deficiency and blood lipid 
levels, Reis et al. (2009), conducted a cross-sectional study amongst 3,528 adolescents 
without a diagnosis of diabetes aged 12 through 19 years, who were participants in 
NHANES (6). This study differed from the prior study in that it focused primarily on 
adolescents but it was also based on the NHANES data and was conducted from 2001 to 
2004. Serum vitamin D levels were assessed using radioimmunoassay techniques. 
Abnormal blood lipid levels for HDL-C and TG were ascertained using the National 
Cholesterol Education Program Adult Treatment Panel III definition modified for age: 
HDL-C < 40 mg/dL and TG > 110 mg/dL (6). For analytical purposes the vitamin D 
levels measured were classified into quartiles, with quartile I, II, III, and IV representing 
a vitamin D level of < 15.00 ng/mL, 15 to 21 ng/mL, 21 to 26 ng/mL and >26.00 ng/mL 
respectively. In comparison to adolescents in the highest quartile, those in the lowest 
quartile of vitamin D had a 50% non statistically significant increased risk for low high-
density lipoprotein cholesterol levels (adjusted OR; 1.54, 95% CI: 0.99 to 2.39). Those in 
the highest quartile of vitamin D level classification did not have a statistically significant 
decreased risk of hypertriglyceridemia, when compared with those in the lowest quartile 
(adjusted OR: 1.00 (CI: 0.49 to 2.04)) (6), adjusting for age, gender, race or ethnicity, 
poverty-to-income ratio, and physical activity.  
 10 
 
Overall this study failed to find any statistically significant association between 
low vitamin D levels or vitamin D deficiency and dyslipidemia as measured by variations 
in TG levels, but did observe the suggestion of an association with low HDL-C levels. 
This study also lacked information on season of vitamin D draw, therefore the observed 
vitamin D levels may not be representative of the average values for the study population. 
Finally, the study did not assess TC and LDL but only focused on HDL and TG which 
may limit its generalizability to adolescents whose dyslipidemia is as a result of an 
abnormality in the levels of LDL and TC.  
The third study by Ashraf et al. (2009), conducted  amongst 51 African American 
obese female adolescents, was the only study that specifically evaluated the association 
between vitamin D deficiency and cardiovascular risk factors, including the full blood 
lipid profile; (TC, TG, HDL and LDL) in adolescent obese females (14). Participants had 
a mean age of 14 + 2 years and mean body mass index (BMI) of 43.3 + 9.9 kg/m2. This 
study utilized a cross-sectional study design, and collected two baseline serum samples of 
both the blood lipid levels and vitamin D levels. Total serum 25-(OH)D was measured 
using liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodology (14). 
A binary classification, with (25(OH)D < 15ng/mL) and (25(OH)D > 15ng/mL) as 
cutoffs, was used in grouping study participants into deficient or sufficient vitamin D 
levels respectively (14). This study failed to show an association between vitamin D 
deficiency and blood lipid levels. The vitamin D deficient groups (n= 31) had a mean 
value of 158.57+ 26.00 and 83.63+41.49 mg/dl for TC and TG respectively, 159.55 + 
18.85 and 88.80 + 50.10mg/dl for TC and TG for those in the vitamin D sufficient group 
(n= 20) (p=0.885 and p=0.693 respectively) (14). The vitamin D deficient groups (n= 31) 
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had a mean HDL and LDL of; 44.34 + 8.56 and 95.69 + 26.17 mg/dl, respectively, as 
compared to 43.35+9.31 and 98.50 + 21.02 mg/dl respectively for the subjects with 
sufficient vitamin D (n=20), (p=0.701 and p=0.692 respectively) (14). After adjusting for 
BMI, a non significant inverse correlation was noted for TC and vitamin D deficiency 
(n= 50, r = -0.011 p=0.94), whereas a positive but non significant correlation was noted 
for HDL (n = 49, r = 0.012 and p=0.94) and LDL (n= 49, r = 0.037 and p=0.80) as well 
as TG (n = 50, r= 0.067 and p=0.64) respectively (14). These findings imply that Ashraf 
et al (2009), found no significant association between serum 25 (OH) vitamin D and 
either; TC, HDL, LDL or TG. 
The restriction of the study population to African Americans, limited its 
generalizability, to a racially diverse population of children with similar characteristics.  
In summary, Kumar et al (2009), observed a significant difference in the decline 
in high density lipoprotein (HDL) and total cholesterol levels amongst vitamin D 
insufficient participants in comparison to vitamin D sufficient participants, additionally 
vitamin D deficiency was observed to be associated with low levels of HDL cholesterol 
irrespective of adiposity or obesity. Reis et al (2009), however, found no significant 
associations between levels (quartiles) of vitamin D with either low high density 
lipoprotein or high triglycerides levels. Similarly Ashraf et al (2009), found no significant 
association between serum 25 (OH) vitamin D and either; total cholesterol, HDL, low 
density lipoprotein or triglycerides. No previous studies have evaluated the association 
between vitamin D deficiency and abnormal blood lipids levels among multiracial 
children and adolescents with diabetes and or obesity, who are at high risk for 
cardiovascular disease (CVD). The studies which have been conducted primarily 
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assessed the association between vitamin D deficiency and blood lipid levels in mainly 
adult populations. To the best of our knowledge two out of the three studies conducted in 
children have failed to show any association between vitamin D and abnormal blood lipid 
levels. These studies are however limited by inadequate assessment of vitamin D 
deficiency because seasonal variations were not accounted for, and in some cases, had a 
small sample size (6, 14, 15).  
 
C. Summary 
The prevalence of dyslipidemia amongst children and adolescents, particularly 
those with prevailing metabolic syndrome such as obesity and diabetes, is steadily 
increasing in the US population. It is thought that there may be an association between 
childhood dyslipidemia and the risk of developing CVD in adulthood. For this reason 
studies have evaluated the possible role of vitamin D deficiency in the development of 
CVD in children. Mechanisms include the role of cardiac myocytes, endothelial, and 
smooth vascular muscle cells in the activation of both the vitamin D receptor and the 1-α-
hydroxylase enzyme which then activates inactive circulating vitamin D precursor 
(25(OH)D) into active vitamin D metabolite and possibly increasing lipoprotein lipase 
enzyme levels and subsequently decreasing TG levels (10). Another possible mechanism 
is as a result of the disruption of the mevalonate pathway (HMG-CoA reductase pathway) 
by the effects of statin drug therapy, which function as inhibitors of the 3-hydroxy-
3methylglutaryl coenzyme A (HMG-CoA) reductase enzyme and subsequently causes an 
increase in 7-dehydrocholesterol (10, 11). The excess 7-dehydrocholesterol in the human 
body is then converted to 25-hydroxycholecalciferol by the action of sunlight or the 
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CYP11A1 enzyme (11). This action leads to an increase in vitamin D levels in the body 
and a corresponding decrease in TG levels possibly due to elevated levels of the 
lipoprotein lipase enzyme resulting from the disruption of the mevalonate pathway (10, 
11).  
There is sparse epidemiologic data on the relationship between vitamin D 
deficiency and dyslipidemia, and majority of prior studies have examined this association 
among adults. Therefore we evaluated the association between vitamin D deficiency and 
blood lipids among children and adolescents, aged between 2 through 21 years, 
diagnosed with either diabetes and/or obesity, and at high risk for cardiovascular disease 
(CVD). 
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CHAPTER III 
SPECIFIC AIM AND HYPOTHESES 
The specific aim of our study was to evaluate the relationship between vitamin D 
deficiency and dyslipidemia among US children and adolescents at high risk for 
cardiovascular disease (CVD). 
The specific hypotheses we addressed in the study were: 
1) We hypothesized that vitamin D deficiency will be inversely related to high serum 
high density lipoprotein (HDL) levels among children and adolescents at high risk 
for CVD. 
2) We also hypothesized that vitamin D deficiency will be positively related to high 
serum low density lipoprotein (LDL), total cholesterol (TC) and triglycerides 
(TG) levels among children and adolescents at high risk for CVD. 
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CHAPTER IV 
METHODS 
A. Cross-sectional Study Design, Setting and Population 
We evaluated the relationship between vitamin D levels and blood lipid levels in 
children and adolescents with diabetes and/or obesity, in a cross-sectional study design. 
Two years (April 2008 through April 2010) of patient data were obtained from the 
Pediatric Endocrinology and Pediatric Weight Management Clinics, of the Baystate 
Medical Center. The data for this cross-sectional analysis were abstracted using a 
retrospective chart review of medical records. The data used for this study consisted of all 
data abstracted through January 24th, 2011.  
 
B. Patient Ascertainment 
Patients eligible for the study were identified from the medical charts and records 
using the International Classification of Diseases, 9th Revision (ICD-9) codes: ICD-9: 
278.0 (obesity), 783.1 (abnormal weight gain), 250.02 (type 2 diabetes), 250.03 (IDDM 
Type 1 without complications uncontrolled), 250.00 (type 2 diabetes, controlled), 
251.1(hyperinsulinism), 250.01 (juvenile diabetes uncomplicated), 253.5 (diabetes 
insipidus). This study was part of a larger study to evaluate the cardiovascular disease 
risk factors in children and adolescents with diabetes and/or obesity. The parent study 
also sought to investigate the effect of low vitamin D levels on levels of the parathyroid 
hormone. Children were referred to this clinic if they had a diagnosis of either obesity or 
diabetes that required medical intervention. Once referred to this specialized clinic, 
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children began a weight and/or diabetes management regime as part of their treatment. 
Data on exposure, outcome and covariates were collected from a routine screening 
procedure for each child during the initial physician visits. Data on both the exposure 
(vitamin D levels) and outcome (blood lipid profiles) as well as covariates such as 
parathyroid levels and serum calcium for each patient was obtained via laboratory testing, 
while data on some covariates such as age (verified from date of birth) gender, ethnicity 
and vitamin D supplementation were self reported by patients. Other covariates such as 
anthropometric measures (e.g. weight and height) were assessed by a trained nurse at the 
time of physician visit and documented in the medical records of each patient. 
Additionally, other covariates such as; body mass index (BMI), BMI- Z-score, glycated 
or glycosylated hemoglobin (HbA1C), and season were calculated from the relevant 
documented medical record data on patients. Physicians generally ordered a laboratory 
profile test for each patient at the initial visit and, when necessary, these tests may be 
repeated again during follow up visits at the physician’s discretion for therapy and 
monitoring purposes. For each patient data for the first 25 (OH) D laboratory draw with 
accompanying lipid blood profile levels were utilized in this study. 
The study is restricted to out-patients of the clinic, aged 2 through 21 years, 
diagnosed of obesity as defined by a BMI > 95th percentile, and/or type 1 diabetes 
mellitus, or type 2 diabetes mellitus (based on these ICD-9 codes:278.0 (obesity), 783.1 
(abnormal weight gain), 250.02 (type 2 diabetes), 250.03 (IDDM Type 1 without 
complications uncontrolled), 250.00 (type 2 diabetes, controlled),  
251.1(hyperinsulinism), 250.01 (juvenile diabetes uncomplicated), 253.5 (diabetes 
insipidus), who in addition also had a documented laboratory measurement of 25-
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hydroxy vitamin D level (25(OH)D) during the study period. Exclusion criteria were 
known gastrointestinal malabsorptive disorder (i.e. celiac disease, cystic fibrosis), known 
parathyroid disease and pregnant adolescents. Also excluded were children and 
adolescents, with a diagnosis of non-essential hypertension and those without a lipid 
assessment within 1 month of the vitamin D assessment. 
Data on exposure, outcome and covariates were obtained from three sources of 
the Pediatric Endocrinology and Pediatric Weight Management Clinic’s patients 
computer database; laboratory data was abstracted from the 1) Clinical Information 
System (CIS) database and 2) Pediatric Endocrinology Dynamic Record Organizer 
(PEDRO) database. Demographic information on patients, was drawn from both the 
Baystate administrative computer database used by Baystate Medical Physician groups; 
3) Centricity Business, and from CIS. The data obtained from these three sources; 1) CIS 
database, 2) Pediatric Endocrinology Dynamic Record Organizer (PEDRO) database and 
3) Centricity Business were merged to create one database for our analysis. These data 
were entered into the database by trained nurses. 
 
C. Vitamin D Levels (Exposure) Assessment 
 Vitamin D levels were assessed as serum 25 hydroxyvitamin D (25(OH) D) 
levels, collected from clinical data of laboratory results in CIS and PEDRO databases. All 
the study exposure data consisted of only vitamin D 25(OH) D assays conducted at the 
Baystate Hospital laboratory using the direct, competitive chemiluminescence 
immunoassay (CLIA) technique with a reference range of 32 - 100 ng/mL. Laboratory 
data was then entered into PEDRO, by a trained nurse and later abstracted for our data 
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analysis by a trained investigator and verified by a trained physician. Serum vitamin D 
levels was categorized into four groups, according to commonly utilized standard limits 
as: 1) severe vitamin D deficiency; less than 25.00 nmol/liter (< 15.00 ng/ml), 2) 
moderate vitamin D deficiency; 25.00–49.99 nmol/liter (15.00 –19.99 ng/ml), 3) vitamin 
D insufficiency, 50.00 –74.99 nmol/liter (20.00 –29.99 ng/ml) and 4) vitamin D optimal 
or normal range, at least 75.00 nmol/liter (≥30.00 ng/ml) similar to what has been done 
by other authors (15). In a separate analysis from the above, vitamin D levels were 
dichotomized as: (≥30.00ng/ml) representing normal vitamin D levels and <30.00ng/ml 
representing vitamin D deficiency. Additionally further analyses were conducted 
evaluating vitamin D levels as a continuous measure. 
 
D. Validity of Exposure Assessment 
The Baystate reference laboratory utilizes an externally and internally validated 
method; direct, competitive chemiluminescence assay (CLIA), for the 25(OH) vitamin D 
(also known as calcidiol, or cholecalciferol) metabolites analysis. The reference range for 
the CLIA analysis is 32-100 ng/mL.  
 
E. Dyslipidemia (Outcome) Assessment 
Based on general recommendations for blood lipid analysis, all outcomes were 
assessed using 12 hour fasting blood samples. All the lipid draws included in this study 
were analyzed at the Baystate reference laboratory; triglyceride (TG) was assessed by 
enzymatic colorimetric GPO/PAP technique. High and low density lipoprotein (HDL and 
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LDL) was by spectrophotometric; diet homogenous; enzymatic colorimetric technique. 
Total cholesterol (TC) was by enzymatic colorimetric techniques. 
A binary classification of low (hypo) or high (hyper) was used in categorizing all 
the four individual blood lipid levels of interest; low density lipoproteins (LDL), high 
density lipoprotein - cholesterol (HDL-C), total cholesterol (TC) and triglycerides (TG). 
High density lipoprotein - cholesterol (HDL-C) and triglycerides (TG) were 
dichotomized using the National Cholesterol Education Program (NCEP), expert panel 
on cholesterol levels in children and adolescents cutoff as; low HDL-C; < 40 mg/dL and 
≥ 40 mg/dL as sufficient (4, 5). Two reference levels were used in determining 
hypertriglyceridemia (high TG levels), based on age; the cutoff point in children aged 2 
to < 10 years was ≥ 110 mg/dL and for children and adolescents aged 10 to 21 years the 
cut point was defined as ≥ 130 mg/dL, which was equivalent to the NCEP definition for 
high LDL (4, 5). Also based on the NCEP guidelines, high TC was defined as ≥ 180 
mg/dL (4, 5). The NCEP cutoffs for high and low levels of the blood lipids represent 
approximately the 95th and 5th percentiles, respectively of the general population. 
 
F. Validity of Outcome Assessment 
The Baystate reference laboratory internally validates the manufacturer’s (Roche) 
repeatability (within run precision, n=21) and intermediate precision (total 
precision/between run precision/between day precision) coefficient of variation (CV) 
periodically. The repeatability CV% for LDL, TC, TG and low HDL are approximately; 
0.81, 0.8, 1.5 and 0.95, respectively whiles the intermediate precision CV% for LDL, TC, 
TG and low HDL are approximately; 1.18, 1.7, 1.8 and 1.3 respectively. For the 
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repeatability analysis, 21 human samples were run, whiles for each intermediate precision 
run, triplicate aliquots were analyzed for 21 days at one run per day.  
 
G. Covariate Assessment 
At the same time as the exposure and outcome assessments, data for covariates 
were also abstracted from the Centricity Business, CIS and PEDRO medical records 
database, for each eligible study participant (Table 1). The covariates of interests  were 
age, sex (gender), serum calcium levels, weight in kilograms, and height in centimeters, 
body mass index (BMI), BMI Z-score, glycated or glycosylated hemoglobin (HbA1C), 
parathyroid hormone (PTH) levels, vitamin D supplementation, seasons (the four 
Northern American seasons; Winter, Spring, Summer and Fall) and ethnicity. Prior 
studies have indicated that age, gender and ethnicity are strong predictors of dyslipidemia 
in children and adolescents especially those with underlining chronic disease conditions 
such as diabetes and obesity (14). 
 
H. Data Analysis Plan 
Specific Aim: we evaluated the relationship between vitamin D levels and the risk 
dyslipidemia (abnormal blood lipid levels) among US children and adolescents with 
diabetes and obesity. 
 
1. Univariate Analysis  
The number and percent of study participants according to inclusion and exclusion 
criteria are presented in Table 2. The distribution (number and percent) of 25-OH vitamin 
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D levels (Table 3), and the distribution of blood lipid levels (Table 4), in our study 
population, are also presented. Both a Pearson’s and Spearman’s correlation analysis was 
conducted to evaluate the correlation between continuous exposure and continuous 
covariates (Table 8).  
 
2. Bivariate Analysis  
We used the two sample t test for continuous covariates and the chi-square test to 
assess categorical covariates as potential confounders by cross-tabulating them with 
binary coded exposure variables (Table 5) and exposure variables categorized into four 
sub-groups on the basis of the previously described standard cutoff values (Table 6), and 
a two sample t test  and Analysis of Variance (ANOVA), for continuous exposure and 
categorical covariates (Table 7) to determine if the observed distribution within our 2X2 
tables fits the expected distributions for large cell frequencies. A similar assessment was 
also done for the outcome variables coded as binary outcome variables (Table 9). For 
2X2 tables with small cell frequencies an appropriate test such as the Fisher’s exact test 
was used for this analysis. The statistical significance of the differences in the 
distributions for all categorical covariates are indicated by P-values. For continuous 
covariates, we calculated two-group t test, to determine the statistical differences in 
continuous outcome variables between levels of the covariates (Table 9). Pearson 
correlation coefficients were used to assess the correlation between the continuous 
exposure or covariate variables and blood lipid levels (Table 10).We also described the 
distribution; number and percentage of the categorical and continuous exposure variable 
within the outcome categories (Table 11). 
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3. Multivariable Analysis  
 We modeled the relationship between levels of vitamin D and all the four types of 
blood lipids, independently by levels within the individual types. This analysis was done 
separately for both categorical and continuous variables using unadjusted and adjusted 
multiple logistic regression and only adjusted multiple linear regression analysis 
respectively (Table 12 and 13). For the 25-OH vitamin D levels dichotomized based on 
widely used cutoffs, the normal level served as the referent group which we compared to 
the deficient group. Similarly the normal group within the second grouping of vitamin D 
levels into four widely accepted categories also served as the referent group for 
comparisons with the other three groups. 
To evaluate confounders we used the backward elimination procedure; for both 
the logistic and linear regression model building respectively, to evaluate the association 
between vitamin D levels and the four blood lipid levels (TC, TG, HDL and LDL) 
adjusting for relevant covariates in separate models. Vitamin D levels were modeled as a 
dichotomous, a categorical and continuous variable respectively in separate models. 
Appropriate dummy variables were created for categorical covariates. All the previously 
mentioned variables (covariates) were evaluated for inclusion in the final multivariable 
logistic regression model as potential confounders, using the backward elimination 
selection method based on Likelihood ratio tests for logistic regression models and on 
Partial Fisher’s (F) tests for the linear regression models. The assessment to determine if 
each covariate should be included in the model was done by initially building univariate 
logistic regression models for each covariate based on the assumption that all continuous 
variables were linear in the logit. Covariates with p-value < 0.25 from the univariable 
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logistic or linear regression model’s likelihood ratio tests or Partial Fisher’s (F) tests, as 
well as other variables of known clinical significance or of relevance to the association 
were included in the initial logistic and linear multivariable model respectively.  
Next based on the Wald’s test p-values from the initial multivariable model, the 
significance or relevance of each covariate in the model was tested, starting with the 
covariate or set of dummy variables with the highest p-value. A Likelihood ratio test with 
a p-value < 0.05 as the level of statistical significance was conducted to determine if the 
covariate being tested should be included in the logistic regression model, changes in the 
coefficients of the other covariates in the model was also considered in decision to retain 
a covariate in the model. A covariate that caused >10% change in the coefficients of the 
other covariates when exclude from the model was retained in the model to be evaluated 
as a confounder. In a similar way as described above for the logistic regression models a 
Partial Fisher’s (F) tests with a p-value < 0.05 was used as the level of statistical 
significance in the linear regression model building procedure  
This process was repeated until all the remaining covariates in the model were all 
of statistical significance or of known clinical significance to the association. Other 
covariates that were not included in the initial multivariable model due to lack of 
statistical significance were then also tested using the backward elimination selection 
process described above, any of these covariates that became statistically significant 
based on the likelihood ratio test or the Partial Fisher’s (F) tests during these steps were 
included in the model, despite their initial exclusion to obtain the preliminary main 
effects model. 
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To assess the assumption that continuous variables in the preliminary main effects 
model, were linear in the logit scale, the design variable method was used, when this 
yielded non linear graphs, next fractional polynomials were utilized to confirm the 
linearity. In some instances in this analysis the assumption of continuous variables being 
linear in the logit was met, but in instances where it was not met for some continuous 
variables, these covariates were recoded using either quartiles or categorizations based on 
cutoff points of inflections on the non linear graph. This recoding process yielded 
multiple linear variables for the specific covariate that had been recorded which was now 
included into the model as quartiles or categorical variables in the final main effects 
multivariable model.  
Possible effect modification by the interactions of pairs of covariates was also 
tested. To evaluate the significance of hypothesized interactions in the logistic regression 
models the Likelihood ratio tests was used and for the linear regression models the Partial 
Fisher’s (F) tests was used, for comparison of the model including the interaction term to 
the main effects model. An analysis that indicated that there were no plausible significant 
effect modifiers of the association, hence no interaction terms were included in any of our 
final multivariable models for the final analysis. Goodness of fit of the models were 
assessed using the Hosmer-Lemeshow test. To assess model discrimination an Area 
under ROC curve was generated. In addition the Hosmer-Lemeshow’s delta deviance test 
was used to assess poorly fit points which were identified as those having significant 
influence on the model deviance, in a similar way for the parameter estimates the 
Pregibon’s delta beta test was used to detect influential points. 
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To assess the effect of the previously identified influential observations on our 
observed results a Sensitivity analysis was conducted to exclude these influential 
observations from the model prior to refitting the model. However the identified 
influential observations represented missing data hence the original final model was 
maintained. Further sensitivity analysis was done to determine if the exclusion of 
younger children (<10) or obese children and adolescents, from the final model changed 
the estimated effects. This analysis also did not yield any different results, hence the 
original final model was maintained. 
Odds ratios and 95% confidence intervals were calculated for the logistic 
regression analysis, whiles regression coefficients and 95% confidence intervals were 
estimated for the linear regression analysis. 
Stata version 11.0 was used for all analyses (Stata Corporation College Station, 
TX). Two-sided p-values ≤ 0.05 were considered statistically significant, with no 
adjustment for multiple comparisons. 
 
I. Significance 
 To the best of our knowledge, to date no study has evaluated the relationship 
between vitamin D levels or deficiency, and abnormal blood lipid levels (dyslipidemia), 
in children with metabolic syndromes such as obesity and diabetes. Given the growing 
incidence of cardiovascular disease risk factors including dyslipidemia amongst children, 
findings could inform more aggressive lifestyle and dietary interventions with vitamin D 
supplementation to reduce the risk of dyslipidemia in high risk children. Other potential 
benefits include the possibility to estimate the prevalence of vitamin D deficiency in this 
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unique population of children in relation to their risk of dyslipidemia. An added benefit 
includes determination of whether the PEDRO database can be supported for future 
clinical research purposes. 
 
J. Human Subjects Protection 
This vitamin D study was approved by the Institutional Review Board (IRB) of 
the Baystate Medical Center. A secondary analysis on the data collected was also 
approved by the Institutional Review Board (IRB) of the School of Public health 
Sciences, University of Massachusetts Amherst. 
Strict measures were put in place to ensure confidentiality of patient data and 
adherence to the IRB protocol. Patient data were coded and de-identified after abstracting 
from the medical records into our database. The study database was securely stored on a 
password protected Baystate Health Center computer, to which only approved study staff 
had access to. Paper charts were immediately returned to the medical records office after 
patient data was obtained in a Baystate office. All study personnel were trained in privacy 
protocols. 
With the exception of the unlikely occurrence of an accidental breach of 
confidentiality or data sharing, there were no known potential risks to study participants 
because there was no direct patient contact and no sensitive patient information was 
accessed. Also the training of study personnel ensured the adherence to privacy protocols. 
There also was minimal to no risks to the physical, psychological, legal, economic and 
social aspects of study subjects. Study participants had no additional benefits, however 
study findings had potential benefits to science and society including; the potential to 
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estimate the prevalence of vitamin D deficiency in children with diabetes or obesity and 
an attempt to relate the level of vitamin D to dyslipidemia in this population. 
 
K. Permission to Access Data 
Permission was sought from the Institutional Review Board (IRB) of the Baystate 
Medical Center, to share the de-identified data with study personnel at the University of 
Massachusetts, Amherst. 
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CHAPTER V 
RESULTS 
From the original study population of 743 participants, a total of 503 (67.7%) 
were excluded and 240 (32.3%) included in the final study sample (Table 2). The 
majority (n = 492, 66.2%) of the exclusions were due to a lack of vitamin D draw during 
the study time period (Table 2). The majority of the participants (n = 175, 72.9%) were 
vitamin D deficient with vitamin D levels ranging from 4.0 to 69.3 ng/ml, with a mean of 
24.65 (standard deviation (SD) 10.33) (Table 3).  
The majority of participants (60.8%) had normal total cholesterol (TC) measures 
(mean TC; 167 mg/dL (34.68 SD)) (Table 4). Overall, across all age groups (2 to 21 
years), half of the study sample (50%), had normal TG levels and 47 (19.6%) had high 
TG levels. Half of the participants had sufficient HDL levels (49.6%) and (21.3%) had 
low levels. Only 16 (6.7%) of had high LDL with the majority (62.1%) having normal 
levels (Table 4).  
The vitamin D deficient participants were more likely to be obese (42.2% body 
mass index (BMI) ≥ 29.0) and (BMIZ score > 1.5) as compared to the patients with 
normal vitamin D levels (26.2% obese) although this was not statistically significant 
(p=0.121). Compared to patients with normal vitamin D levels mean weight, categorical 
BMIZ, mean serum calcium (Ca), mean parathyroid hormone (PTH) levels and ethnicity 
were significantly higher among vitamin D deficient patients (Table 5). On the contrary 
age, sex (gender), height, body mass index (BMI), mean BMI Z-score (BMIZ), vitamin D 
supplementation, glycated hemoglobin (HbA1C) and season did not differ significantly 
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between patients with normal vitamin D levels and those with vitamin D deficiency 
(Table 5). 
We then evaluated whether covariates differed according to category of vitamin D 
deficiency (Table 6). Our observations were similar to those previously described with 
dichotomized vitamin D levels (Table 5), however, contrary to our prior observation age, 
BMI, and height, differed significantly among patients according to categories of vitamin 
D (Table 6). Specifically, severely vitamin D deficient participants were the oldest, tallest 
and had the highest PTH levels (Table 6). 
We then evaluated the distribution of covariates according to continuous vitamin 
D levels; mean vitamin D levels differed significantly across categories of BMI, BMIZ, 
season and ethnicity (Table 7). The lowest mean vitamin D level occurred in winter, 
whiles the highest occurred in the summer season. Mean vitamin D levels were highest 
and almost equivalent amongst Caucasian and Asian patients, as compared to African 
Americans / Blacks (Table 7).  
We then evaluated Pearson’s and Spearman’s correlation between continuous 
covariates and vitamin D levels. Weight, body mass index Z-score (BMIZ) and 
parathyroid hormone (PTH) were  negatively and significantly correlated with vitamin D, 
while age, height, serum calcium (Ca) and glycated hemoglobin (HbA1C), were not 
significantly correlated (Table 8). 
We then evaluated the distribution of covariates, according to normal vs. 
abnormal blood lipid levels (Table 9). Patients with high mean glycated hemoglobin 
(HbA1C) (poor control) were significantly more likely to have high TC as compared to 
those with low HbA1C (P = 0.004) (Table 9). Patients who were younger and heavier 
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were more likely to have high TG. Children who were Caucasian or Hispanic were more 
likely to have high TG as compared to children who were African American/Black. 
Patients who were heavier and those with acceptable glycated hemoglobin (HbA1C) 
levels were more likely to have low HDL. 
We then evaluated the correlation between vitamin D and covariates with blood 
lipid levels (Table 10). Both vitamin D level and HbA1C were positively and 
significantly correlated with total cholesterol (TC); (r = 0.18, P = 0.0084) and (r = 0.21, P 
= 0.0049) respectively. Each unit increase in vitamin D level (vdl), resulted in a 21% 
decrease in TG; (r = -0.21, P = 0.006), on the contrary a one kilogram increase in weight 
and a unit increase in BMIZ lead to a corresponding increase in TG; (r = 0.22, P = 
0.0038) and (r = 0.32, P =<0.0001) respectively (Table 10). Each unit increase in vitamin 
D level (vdl), age or HbA1C, corresponded to an increase in HDL (Table 10). The 
relationship between both weight and BMIZ with HDL were reversed and in both cases 
the observed inverse correlation was statistically significant; (r= -0.35, P = <0.0001) and; 
(r= -0.21, P =0.0074) respectively (Table 10). Additionally each unit increase in vitamin 
D level (vdl), or height corresponded to a weak reverse effect on LDL levels; (r= -0.17, P 
= 0.0265) and (r= -0.16, P = 0.0424) respectively (Table 10).  
In a bivariate analyses we assessed the crude relationship between our exposure 
variable (vitamin D dichotomized, categorized and continuous) and dichotomized levels 
of each of the four outcome variables (blood lipids) (Table 11). Participants with 
deficient levels of vitamin D were significantly more likely to have high TG, and low 
HDL but less likely to have high TC and high LDL compared to those with normal 
vitamin D levels (Table 11). Compared to patients with normal vitamin D levels, patients 
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with either vitamin D insufficiency, moderate or severe vitamin D deficiency were more 
likely to have low HDL, but less likely to have high TC, high TG and high LDL (Table 
11). Mean vitamin D levels were more likely to lower among patients with high TG and 
low HDL but similar among patients with high TC and high LDL in comparison to 
vitamin D levels among patients with normal blood lipids (Table 11). 
We then evaluated the association between vitamin D levels and the risk of 
dyslipidemia (Table 12). In an unadjusted logistic regression model, moderately deficient 
vitamin D patients had 1.68 times the odds of high total cholesterol compared to patients 
with normal vitamin D levels (95% Confidence Interval (95% CI; 0.72 to 3.94). After 
adjusting for age, BMIZ and HbA1C, findings were strengthened (OR = 2.9, 95% CI; 
0.95 to 8.82) (Table 12). In an unadjusted logistic regression model, severely vitamin D 
deficient patients had 3.5 times the odds of high triglycerides, compared to patients with 
normal vitamin D levels (OR 3.50, 95CI% 1.25 to 9.79) (Table 12). A P- value for trend; 
0.012 indicated a significant association between decreasing levels of vitamin D and the 
odds of high triglycerides. Adjustment for PTH, BMIZ and ethnicity strengthened the 
association, but confidence intervals were wide (OR 11.65, 95CI% 1.93 to 70.27) (Table 
12). An overall trend of a positive association between decreased levels of vitamin D in 
relation to the risk of high triglyceride was observed (P- value for trend =  0.006) (Table 
12). 
In an unadjusted logistic regression model, a protective effect of high triglyceride 
was observed amongst patients with vitamin D levels above the mean value; irrespective 
of adjustments for potential confounding; unadjusted OR; 0.95 (95% CI: 0.91 to 0.98) 
and multivariable OR (0.91) adjusting for PTH, BMIZ and ethnicity 95% CI: 0.86 to 0.97 
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(Table 12). In an unadjusted logistic analysis vitamin D deficient patients had 3.06 times 
the odds of low high density lipoprotein as compared to patients with normal vitamin D 
levels. This observed risk was attenuated after adjusting for BMIZ and ethnicity (OR = 
2.51, 95% CI: 0.94 to 6.69) (Table 12). In an adjusted logistic regression analysis 
moderately and severely vitamin D deficient patients had 4.02 and 5.24 times the odds of 
low high density lipoprotein respectively, as compared to patients with normal vitamin D 
levels (Table 12). After adjusting for confounding by BMIZ and ethnicity the risk 
amongst moderately vitamin D deficient patients was elevated whiles an attenuated risk 
was observed amongst severely vitamin D deficient patients (Table 12). 
Finally, we evaluated the association between vitamin D levels and risk of 
dylipidemia in a linear regression analysis (Table 13). After adjusting for potential 
confounding by gender, HbA1C, ethnicity and season, a one ng/mL change in vitamin D 
deficiency, vitamin D insufficiency, moderate or severe vitamin deficiency was 
associated with a mean increase of 14.82 mg/dL, 11.8 mg/dL, 21.75 mg/dL and 17.68 
mg/dL in total cholesterol levels respectively (Table 13). On the contrary a one unit 
(ng/mL) change in continuous vitamin D levels was associated with a mean decrease of 
0.58 mg/dL, in total cholesterol levels (Table 13). After adjusting for BMIZ, ethnicity 
and parathyroid hormone (PTH), in comparison to patients with normal vitamin D, 
deficiency in patients was positively associated with the risk of high triglycerides (TG) 
(Table 13). A positive and significant association was observed between categorical 
vitamin D levels and the risk of high TG, although the trend was not uniform across 
strata; P value for trend = 0.002 (Table 13). Each one unit (ng/mL) reduction in vitamin 
D levels was associated with a 2.14 mg/dL increase in high TG levels, P - value for trend 
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= <0.001) (Table 13). Across strata of categorical vitamin D levels the magnitude of 
association between vitamin D levels and the risk of low HDL, increased with decreasing 
levels of vitamin D deficiency (Table 13). Similarly each one ng/mL increase in vitamin 
D levels was associated with a 0.37 increase in the risk of low HDL, P - value for trend 
(0.004) (Table 13). Lastly, each one ng/mL decrease in vitamin D levels was associated 
with a mean increase of 0.51 mg/dL in the risk of high LDL, P - value for trend (0.019), 
although there was no consistent association across increasing category of vitamin D 
deficiency. 
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CHAPTER VI 
DISCUSSION 
In this cross-sectional analysis of the relationship between vitamin D levels and 
dyslipidemia, we observed that children and adolescents with moderate vitamin D 
deficiency had an almost 3-fold increased risk of high TC compared to children with 
normal vitamin D levels. Severe vitamin D deficiency was associated with a strong and 
significant increased risk of low HDL as well as high TG as compared to children with 
normal vitamin D levels; with a significant dose-response relationship. We did not 
observe a statistically significant relationship between vitamin D deficiency and neither 
high TC nor high LDL, however there was the suggestion of an increased risk. The lack 
of association with high LDL could possibly be due to the small number of cases of high 
LDL and therefore limited power. In addition, in linear regression analyses, we did find 
that an increase in vitamin D deficiency was associated with a significant mean increase 
in all four measures of dyslipidemia. 
 
A. Study Limitations 
1. Nondifferential Misclassification of Exposure 
Although our measures of 25-hydroxy vitamin D levels (exposure) came from 
validated standardized laboratory tests done at the Baystate Health Center’s laboratory, 
the exposure assessment was via laboratory assays, for which there could have been a 
slight chance of random measurement inaccuracies occurring as a result of human factors 
such as analysis setup and interpretation and recording of results, which could have led to 
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slight variations or inaccuracies in our 25-hydroxy vitamin D measures. These random 
errors however should not have differed amongst our blood lipid levels in a systematic 
way, hence it is unlikely that some non-differential misclassification of exposure could 
have occurred via this avenue, which would have potentially led to an underestimation of 
our effects estimates and biased our results towards the null value, by equally distorting 
the true vitamin D levels amongst dylipidemia cases and non-cases. We categorized our 
exposure (vitamin D levels), using widely used cutoff points to minimize the impact of 
non-differential misclassification of exposure on our effect estimates. Hence within these 
categories each participant’s, exposure level was accurately represented and a 
comparison between these categories could then help minimize possible misclassification 
between vitamin D categories in relation to dyslipidemia status. Additionally this error 
was minimized by using trained laboratory personnel in obtaining our laboratory 
measures on exposure. 
 Secondly, due to the observational measure of our study we used single 
measurements of serum 25-hydroxy vitamin D as a proxy for the vitamin D status of our 
study participants, although this is thought to be the best measure of vitamin D status and 
hence is widely used. This measure however may not reflect long term vitamin D status, 
because serum 25(OH) D, which indicates vitamin D made cutaneously as well as that 
derived from diet and supplements has a half – life of 15 days (23). Hence, although we 
collected data on vitamin D supplementation, our reliance on serum 25-hydroxy vitamin 
D may have introduced some nondifferential misclassification in our evaluation of 
vitamin D status. The occurrence of this nondifferential misclassification could have 
potentially biased our results towards the null and thereby resulted in a reduction of the 
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effect estimates for our relationship between 25-hydroxy vitamin D levels (25(OH) D) 
and dyslipidemia in these children. The effect of this misclassification would have been 
minimal, because proxy measures such as those we used are considered the best measure 
of vitamin D status and is widely used and accepted in analysis.  
 
2. Nondifferential Misclassification of Outcome 
Blood lipid levels were abstracted from laboratory results documented in medical 
records for patients with a diagnosis of obesity and or type 1 and 2 diabetes mellitus 
using specific International Classification of Disease version 9 (ICD 9) codes for these 
two disease conditions. Also all cases of blood lipid levels were confirmed by a trained 
investigator through chart review. Two trained physicians checked and verified the 
outcome measures in the database. If during the data abstraction process however, cases 
of dyslipidemia were incorrectly entered into the database, this could have attenuated our 
effect estimates and biased our results towards the null, but the occurrence of this is 
highly unlikely, because of the data verification steps employed to ensure that the data 
was accurately abstracted from the medical charts and entered correctly into our database.  
If some study participants did not fast 12 hours prior to their laboratory testing as 
was required, their measurements of the abnormal blood lipid may have been artificially 
elevated and not reflective of their true values and as such could have led to an 
underestimation of the effect estimates and biased our results towards the null value. The 
occurrence of this situation was highly unlikely because participants were advised to fast 
before the laboratory testing and their fasting status was verbally ascertained prior to 
testing via self report. Studies show that TG in particular is elevated postprandial 
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although the physiological mechanism is poorly understood (24, 25). In contrast, in 
comparison to fasting lipid profiles of the general population, Langsted et al. (2008) 
observed negligible decreases in levels of TC, HDL and LDL measured postprandial 
(25). 
We relied on a single measurement of blood lipids, but both analytical 
inaccuracies and imprecision resulting from laboratory methods of blood lipid assessment 
as well as biologic or physiologic variation can influence blood lipid levels (26-28). In 
terms of inaccuracy resulting from laboratory methods, previous repeatability (within-run 
precision) and intermediate precision (total precision / between run precision / between 
day precision) validation analyses done at the Baystate laboratory have indicated 
relatively small coefficients of variation. 
In terms of inaccuracy resulting from use of a single blood lipid measure to 
accurately represent an individual’s long term blood lipid profile, Kafonek et al. (1992), 
evaluated the biological variability in TC, HDL, LDL and TG. The authors calculated 
physiological coefficients of variations (CVp) to take into account the total physiological 
and analytical variations per patient from triplicate samples, taken at baseline from each 
patient prior to lipid control treatment. They observed the following median physiological 
coefficients of variation: 5.0% for TC, 17.8% for TG, 7.1% for HDL and 7.8% for LDL 
and concluded that when triplicate blood samples are obtained  in sequence, a single 
measure of blood lipids obtained from these analysis will be representative of an 
individual’s blood lipid levels within these ranges of precision (± 1, ±4, ± 11 and ± 8 
CV% for TC, TG, HDL and LDL respectively) (27). It has been reported that physiologic 
variation could result in a 3%, or 5% or 10% change in serum TC levels (26). Shumak et 
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al (1993) suggests that a non linear decline in the CVs is noted with multiple lipid 
sampling per person; the authors observed CVs ranging between approximately  4% to 
10% for TC, 7% to 14% for LDL, 6% to 13% for HDL and 19% to 51% for TG (26). 
Additionally, for example, the CV in females change from 8.6% to 6.5% after duplicate 
cholesterol sampling done individually, and a 50% reduction in the CV can be obtained 
from calculations from five cholesterol measures. Based on these observations Shumak et 
al (1993), concluded that although repeated lipid measures prior to lipid control therapy 
decisions have been suggested, very little precision is achieved via repeated 
measurements.  
In an evaluation of the impact of physiologic and analytical variations on the use 
of a single lipid measure, to accurately assign risk categories in 51 individuals from 
triplicate lipid samples, Bookstein et al. (1990) observed 5% day-to-day variability in 
TC, 20% in TG, 10% in HDL and 8% in calculated LDL respectively (28). However, 
Bookstein et al. (1990) also observed that, reliable TC and LDL measures , based on the 
NCEP guidelines may be obtained from a single lipid measurement, if measured TC 
levels were < 185 mg/dL or ranged between 215 to 225 mg/dL or was >225 mg/dL, 
likewise for LDL, reliable measures could be obtained for LDL levels < 116 mg/dL or > 
174 mg/dL from single lipid measures (28). Thus misclassification due to variations in 
lipid levels may be unavoidable in the context of single or duplicate lipid level sampling, 
and particularly when lipid levels fall within 10% of the documented NCEP cutoff points 
(28).  
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In summary, our use of single measurements of lipid values, which are susceptive 
to physiologic (natural) variations, may have led to misclassification of patients risk 
categories (26). 
 
3. Selection Bias 
 Due to the uniform admission of participants into our study, using a uniformly 
applied selection criteria as defined by the availability of data on the first measured value 
of 25 (OH) D levels within the study period, selection bias was highly unlikely in our 
study. Also knowledge of the dyslipidemia of study participants was masked or unknown 
to the physicians and investigator in the selection of study participants into the study. For 
example, selection bias could only have occurred, if study participants were selected into 
the study based on their diagnosis of dyslipidemia, which in this case was not the 
situation, or if patients with vitamin D deficiency and dyslipidemia were sicker than other 
patients and as such were more motivated to follow through with the physician referral 
and hence had a higher chance of being selected into our study compared to other 
participants. Although this was not the case, if this had happened it would have led us, to 
miss some participants who had normal vitamin D levels or normal blood lipid levels. 
This then could have led to an overestimation of our effects estimates and our results 
would have been biased away from the null value, this we believe was an unlikely 
occurrence in our study.  
 Another avenue for selection bias to have occurred in our study was due to the 
fact that 492 patients (66.2%), out of the total original study sample of 743 (100%) 
patients, were excluded from our final study sample due to lack of vitamin D draw in the 
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study period. Ideally we would have liked to conduct a sensitivity analysis comparing the 
characteristics of the excluded patients to those included in the final study sample, to 
assess the potential of selection bias in our study via patient inclusion or exclusion 
criteria. However, we were unable to do this because our study database lacked data on 
the excluded patients. 
 
4. Information Bias 
The physicians were blinded to the vitamin D and dyslipidemia disease status of 
our study participants thus reducing the possible occurrence of information bias, through 
the data validation process. Surveillance bias was also very unlikely in our study design 
since the data collected was from laboratory records. No information was gathered from 
the participants hence there was no possibility of recall bias in the exposure data 
collection from our study participants. Another possibility of information bias would 
have been due to variations in the assessments of individual measures of 25(OH) D levels 
and blood lipid levels due to variations in the time at which each participant had these 
measure taken. The time varied within our study period, hence some patients may have 
been visiting the diabetes management clinic and receiving some counseling and if they 
were compliant to the recommendations for a healthy lifestyle and as such had changed 
their diet and lifestyle prior to the assessment of 25(OH) D) and blood lipid levels, the 
additional counseling could have led these patients to modify lifestyle and diet which 
would have impacted the blood test results. If this had happened then these patients could 
for example have taken unprescribed vitamin D supplements or multivitamins or 
intentionally eaten foods known to be vitamin D rich as well as low fat foods as a way of 
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managing their vitamin D deficiency and dyslipidemia status which they had become 
aware off after consulting with a physician. This could then have led to an 
underestimation of their true effects estimates within our study period and biased our 
results towards the null value, because they would have already started managing their 
vitamin D levels and dyslipidemia status before data assessment was done for our study.  
 
5. Temporal Bias 
One major limitation of our cross-sectional study design, due to its observational 
nature was our lack of temporality between vitamin D levels and the risk of dyslipidemia 
(temporal relationship between exposure and the occurrence of the disease). Hence 
causality could not be established due to the difficulty in demonstrating if the vitamin D 
deficiency preceded the dyslipidemia. Despite this inability to establish a cause-and-
effect relationship the study granted us a hypothesis generating ability. In addition the 
extreme obesity of the study participants may have masked the relevant associations 
between vitamin D deficiency and dyslipidemia. This could have happened because 
vitamin D is a fat soluble vitamin, hence when in excess it is stored in body fat, therefore 
for individuals who were obese and had excess fat stores, the bulk of their vitamin D may 
have been be trapped and stored in the excess fat hence, increasing their risk of vitamin D 
deficiency (7). As such, the observed significant increase in odds of high TC, low HDL 
as well as high TG amongst children and adolescents with below optimal vitamin D 
levels compared to children with normal vitamin D levels, could possibly be due to the 
fact that some of their serum vitamin D was being trapped within the elevated serum 
blood lipid levels, implying a possible reverse causality. A randomized clinical trial 
 42 
 
would be needed to assess this possible reverse causality and thus ascertain the 
relationship between vitamin D and dyslipidemia in these children and adolescents. 
 
6. Confounding 
Within our multivariable linear and logistic regression model, we controlled for 
and evaluated many known risk factors for dyslipidemia and other cardiovascular disease 
risk factors recognized in literature as potential confounders of our vitamin D and lipid 
levels association, using a Directed Acyclic Graph (DAG).  
Adequate sunlight exposure and normal vitamin D levels are highly positively 
correlated. Both vitamin D deficiency (exposure) and dyslipidemia (high TC, high TG, 
high LDL and low HDL - disease) are independently and negatively associated with 
adequate sunlight exposure. Yamazaki et al. (1998), observed significant increases (10.0 
+ 6.7 to 38.9 + 38.0 pmol/cm2) in the levels of cholesterol hydro peroxides (Ch 7-OOHs) 
in human skins after three hours of 10 – 40mJ/cm2/min of sunlight exposure (29). Hence 
if adequate sunlight exposure was not accurately controlled for, it could have acted as a 
confounder and would have led to an overestimation of our crude estimates (results) in 
relation to the null value. We minimized this concern by evaluating data on seasons of 
vitamin D level measurements within our models, this we did by collecting data on 
exposure and outcome for participants within a two year period that encompassed 
duplicates of the four seasons of the Northeastern US. Thereby reducing concerns 
regarding for variations in vitamin D draws due to change in sunlight exposure as a result 
of seasonal variations. Hence we believe that the occurrence of confounding due to 
inadequate sunlight exposure evaluation in our study was highly unlikely. 
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Our dataset did not include information on the physical activity of participants, 
which is negatively and independently associated with both vitamin D deficiency and 
dyslipidemia (high TC, high TG, high LDL and low HDL disease). Therefore not 
controlling for it in our multivariable analysis could have led to an overestimation of the 
association between vitamin D deficiency and dyslipidemia. We believe the effect of not 
controlling for physical activity as a variable was minimized because we included BMI 
and BMI Z-scores in our analysis and BMI is highly correlated with physical activity. 
However, there is still likely residual confounding due to physical activity which we were 
unable to adjust for because our dataset had no information on directly measured physical 
activity of our patients.  
 
7. Generalizability  
Our results may not be generalizable to the general population of children and 
adolescents, but may only be generalized to children and adolescents aged 2 to 21 years, 
with a diagnosis of type 1 and type 2 diabetes mellitus and / or obesity (BMI >95th 
percentile), living in geographical regions or temperate countries with seasonal variations 
similar to the Northeast US, with no gastrointestinal malabsorptive disorder (i.e. celiac 
disease, cystic fibrosis) and no known parathyroid disease.  
It has been established that vitamin D levels are lower in darker pigmented people 
than light skinned people (7, 30). Hence, differences in skin pigmentation may cause 
biological differences to exist in how vitamin D deficiency influences dyslipidemia and 
thus possibly limit the generalizability of our findings to children and adolescents with 
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skin pigmentations similar to that of our study population (mainly light skinned 
participants).  
 
B. Consistency with Prior Literature 
Despite immense recent interest in vitamin D deficiency and dyslipidemia in 
children and adolescents, only three out of the eleven epidemiologic studies investigated 
this association in children and adolescents ≤ 20 years old; Kumar et al (2009), Reis et al 
(2009) and Ashraf et al (2009). Our findings were inconsistent with that of Kumar et al 
(2009), who in their cross-sectional study design, observed amongst vitamin D 
insufficient participants in comparison to vitamin D sufficient participants, a significant 
difference in the decline in high density lipoprotein (HDL) (difference: -2.29 mg/dL; 
95% CI -3.57 to -1.01, p = 0.001) and total cholesterol levels, (difference: -3.66 mg/dL; 
95% CI -7.09 to -0.23, p = 0.04) respectively, additionally vitamin D deficiency was 
observed to be associated with low levels of HDL cholesterol (difference: -3.03 mg/dL, 
95% CI -5.02 to -1.04, p = 0.004) irrespective of adiposity or obesity. In contrast, we 
found statistically nonsignificant odds ratios (OR) of 1.52 (95% CI 0.50 to 4.56) and OR 
of 2.51 (95% CI 0.94 to 6.69) amongst vitamin D insufficient and deficient participants 
respectively, in comparison to vitamin D sufficient participants in relation to the risk of 
low HDL. We also observed no significant associations between vitamin D deficiency 
amongst patients in comparison to normal vitamin D levels and the risk of high TC (OR 
= 1.95; 95% CI: 0.85 to 4.46) . 
Both Reis et al. and Ashraf et al. observed null findings in their cross-sectional 
design studies. Despite their relatively large study sample, Reis et al. did not observe 
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significant associations between levels (lowest quartiles compared to highest) of vitamin 
D with either low high density lipoprotein (adjusted OR: 1.54, 95% CI: 0.99 to 2.39) or 
high triglycerides levels (adjusted OR: 1.00, 95% CI: 0.49 to 2.04). Similarly, Ashraf et 
al (2009), found no significant association between serum 25 (OH) vitamin D and either; 
total cholesterol (r = -0.011, p = 0.94), triglycerides (r = 0.067, p = 0.64), HDL (r = 
0.012, p = 0.94), or low density lipoprotein (r = 0.037, p = 0.80). In contrast we observed: 
(r = 0.18, p = 0.0084), (r = -0.21, p = 0.006), (r = 0.22, p = 0.0039) and (r = 0.17, p = 
0.0265) for the same comparisons. Differences in findings between our study and that of 
these 3 prior studies among youth may be due to lack of consistency in the categorization 
of both exposure and outcome, variations in covariate assessments such as inadequate 
adjustment of confounding leading to the possibility of residual confounding, or 
unevaluated effect modification and differences in study population characteristics and 
distribution. 
Although the biological mechanism linking vitamin deficiency to the risk of 
dyslipidemia is still poorly understood, there are three proposed possible indirect 
mechanisms. The first mechanism involves the activation of the vitamin D receptor; the 
second mechanism is a possible consequence of the effect of statin drug therapy on the 
disruption of the mevalonate pathway (HMG-CoA reductase pathway); and the third 
mechanism is as a result of the elevation of peripheral insulin resistance in the body.  
 
C. Significance 
Our findings relate vitamin D deficiency to dyslipidemia in children with diabetes 
and obesity and add to the sparse body of literature in this area. We found that children 
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and adolescents with varying levels of vitamin D deficiency had significantly increased 
risk of high TC, low HDL, and high TG. Findings can inform more aggressive lifestyle 
and dietary interventions with vitamin D supplementation to reduce the risk of 
dyslipidemia in high risk children. Findings also shed light on the prevalence of vitamin 
D deficiency in this unique population of children and adolescents.  
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Table 1. Classification of study variables: Baystate Medical Children’s Hospital vitamin 
D deficiency and dyslipidemia study, 2008 to 2010, (n=240). 
Name  Description Type 
Outcome variables   
   
TCcat Total Cholesterol Dichotomous 
      ≥ 180 mg/dL (high)  
      < 180 mg/dL (normal)  
   
TC  continuous TC continuous 
   
TGcatlo  Triglycerides (cut points for 2 to <10 years ) Dichotomous 
       ≥ 110mg/dL  (high)  
       < 110mg/dL  (normal)  
   
TGcathi  Triglycerides (cut points for 10 to 21 years ) Dichotomous 
       ≥ 130mg/dL  (high)  
       < 130mg/dL  (normal)  
   
Tgcatagett Triglycerides: binary classification for all ages (2 to 21 years) Dichotomous 
       High  
       Normal  
   
TG  continuous TG continuous 
   
HDLcat High density lipoprotein cholesterol Dichotomous 
        <  40mg/dL  (low)  
        ≥  40mg/dL  (sufficient)  
   
HDL continuous HDL continuous 
   
LDLcat Low density lipoprotein – cholesterol Dichotomous 
         ≥ 130mg/dL  (high)  
         < 130mg/dL  (normal)  
   
LDL continuous LDL continuous 
Exposure variable  
VDLcat4 25-OH vitamin D levels Categorical 
          < 15.00 ng/ml             (severe deficiency)  
          15.00 – 19.99 ng/ml   (moderate deficiency)  
          20.00 – 29.99 ng/ml   (25(OH)D insufficiency)  
          ≥30.00 ng/ml              (normal or optimal)  
   
VDLcat2 25-OH vitamin D deficiency Dichotomous 
          <30.00 ng/ml       (Deficient)  
          ≥30.00 ng/ml       (Normal)  
   
VDL Continuous vitamin D levels Continuous 
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Table 1. contd. 
Covariates     
Agecat2 Age at study enrollment and assessment Categorical 
          1=  2 to <10 years  
          2 = 10 to 21 years  
   
Age continuous Individual ages at study enrollment and assessment continuous 
   
Sex Gender Dichotomous 
          1 = Male  
          2 = Female  
   
Ca Serum Calcium  Continuous 
   
Wgt Weight in kg. Continuous 
   
Hgt Height in cm Continuous 
   
BMIcat4 Body Mass Index Categorical 
           1 = BMI < 19.8 kg/cm2             (Underweight)  
           2 = BMI 19.8  - 26.0 kg/cm2     (Normal)  
           3 = BMI > 26.0 - 29.0 kg/cm2    (Overweight)  
           4 = BMI ≥ 29.0 kg/cm2                  (Obese)  
   
BMIZ BMI Z score Continuous 
   
BMIZcat BMI Z score categories Categorical 
                1 = BMIZ >1.5   (Overweight / Obese)  
            0 = BMIZ ≤1.5   (Normal)  
   
A1C Glycated or glycosylated hemoglobin (HbA1C)  Continuous 
   
A1Ccat Glycated or glycosylated hemoglobin Categorical 
           1 = HbA1C >8.0 (Bad HbA1C control)  
           0 = BMIZ ≤8.0   (Good HbA1C control)  
   
PTH Parathyroid Hormone Continuous 
   
VDS Vitamin D supplementation Categorical 
           1= Yes  
           2= No  
   
SEASON Seasons of  the year in US Categorical (Nominal) 
           1= Winter  
           2= Spring  
           3= Summer  
           4= Fall  
   
ETH Ethnicity Categorical (Nominal) 
           1 = Caucasian  
           2 = Asian  
           3 = African American / Black  
           4 = Hispanic / Latino  
           5 = Other  
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Table 2. Characteristics of Baystate vitamin D deficiency and dyslipidemia  
2008- 2010 study population: inclusion and exclusion criteria (n=240) 
 N % 
Original study sample 743 100 
Exclusion criteria   
          No vitamin D draw in study date range 492 66.2 
          Medical visits outside study dates  1 0.1 
          Medical based exclusion 7 0.9 
          Age exclusion (<2 age >21 years) 3 0.4 
          Multiple exclusion criteria 5 0.7 
Total Excluded  503 67.7 
Final study sample 240 32.3 
          By diagnostic group   
                Type I Diabetes 128 53.3 
                Type II Diabetes 13 5.4 
                Obesity 99 41.3 
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Table 3. Distribution of 25-OH vitamin D  measures and levels  among Baystate 
vitamin D, 2008- 2010 study population (n=240). 
  N % 
 25-OH Vitamin D  levels   
          <30.00 ng/ml    (Deficient) 175 72.9 
          ≥30.00 ng/ml    (Normal) 65 27.1 
 N % 
25-OH Vitamin D  levels   
        < 15.00 ng/ml             (Severe deficiency ) 42 17.5 
       15.00 – 19.99 ng/ml    (Moderate  deficiency) 46 19.2 
       20.00 – 29.99 ng/ml    (Insufficiency) 87 36.3 
        ≥30.00 ng/ml              (Normal or Optimal) 65 27.1 
 Mean (SD) 
Median 
(Range) 
25-OH Vitamin D  measures (ng/ml) 
24.65 
(10.33) 23.2 (4 - 69.3) 
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Table 4. Distribution of blood lipid levels among Baystate vitamin D, 2008- 2010 study 
population. 
  N % 
Total Cholesterol (TC)   
       ≥ 180 mg/dL (high) 69 28.8 
       < 180 mg/dL (normal) 146 60.8 
       Total 215 89.6 
 Mean (SD) Median (Range) 
TC - continuous 167.0 (34.68 ) 166 (77 -336) 
Triglyceride (TG 2 to <10 years)   
      ≥ 110mg/dL  (high) 10 29.4 
      < 110mg/dL  (normal) 10 29.4 
       Total 20 58.8 
Triglyceride (TG 10 to 21 years)   
      ≥ 130mg/dL  (high) 37 18 
      < 130mg/dL  (normal) 110 53.4 
      Total 147 71.4 
Triglyceride (TG 2 to 21 years)   
      High 47 19.6 
      Normal 120 50 
      Total 167 69.6 
 Mean (SD) Median (Range) 
TG - continuous 109.0 (60.85) 91 (20 - 518) 
High density Lipoprotein cholesterol (HDL-C)   
       <  40mg/dL  (low) 51 21.3 
       ≥ 40mg/dL  (sufficient) 119 49.6 
       Total 170 70.8 
 Mean (SD) Median (Range) 
HDL - continuous 48.5 (13.46) 46 (20 - 88) 
Low density Lipoprotein cholesterol (LDL-C)   
      ≥ 130mg/dL  (high) 16 6.7 
      < 130mg/dL  (normal) 149 62.1 
      Total 165 68.8 
 Mean (SD) Median (Range) 
LDL - continuous 95.9 (29.93) 94 (30 - 251) 
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Table 5. Distribution of covariates according to dichotomous 25-OH vitamin D  levels: 
Baystate vitamin D 2008- 2010 study population (n = 240). 
  25-OH Vitamin D  levels   
  Deficient Normal p value* 
n 175 (72.9%) 65(27.1%)  
Age, categorized (Agecat2)    
       2 to <10 years  23(13.1%) 11(16.9%) 0.455 
      10 to 21 years  152 (86.9%) 54 (83.1%)  
Age 13.92 (3.55 SD) 14.76 (3.66 SD) 0.1055 
Sex   0.985 
      Male  81 (46.3%) 30 (46.2%)  
      Female 94 (53.7%) 35(53.9%)  
Weight 76.35 (32.71SD) 68.01 (22.29SD) 0.0589 
Height 158.10 (16.14SD) 159.94 (13.07SD) 0.4121 
BMI   0.121 
      BMI < 19.8 (Underweight) 28 (16.2%) 11 (16.9%)  
      BMI 19.8 - 26.0 (Normal) 52 (30.1%) 28 (43.1%)  
      BMI > 26.0 - 29.0 (Overweight) 20 (11.6%) 9 (13.9%)  
      BMI ≥ 29.0 (Obese) 73(42.2%) 17(26.2%)  
BMI Z-score (BMIZ) 2.25(7.54SD) 1.31 (0.90SD) 0.3195 
BMIZ categorical   0.016 
      BMIZ > 1.5 (Obese) 104(60.5%) 28(43.1%)  
      BMIZ ≤ 1.5 (Normal) 68(39.5%) 37(56.9%)  
Vitamin D supplementation   0.341 
      Yes 4 (2.3%) 3 (4.6%)  
      No 171 (97.7%) 62 (95.4%)  
Serum Calcium (Ca) 9.83 (0.37SD) 9.70 (0.48 SD) 0.0479 
Glycated hemoglobin (HbA1C)   0.704 
      HbA1C ≤ 8 (Acceptable) 85 (60.7%) 30 (57.7%)  
      HbA1C > 8 (Bad control) 55 (39.3%) 22 (42.3%)  
Glycated hemoglobin (HbA1C) 7.80 (2.11 SD) 7.84 (1.47 SD) 0.9023 
Parathyroid Hormone (PTH) 36.81 (14.99SD) 31.95 (8.70SD) 0.022 
Seasons of  the year in US   0.103 
      Winter 34 (19.4%) 5 (7.7%)  
      Spring 33 (18.9%) 10 (15.4%)  
      Summer 59 (33.7%) 29 (44.6%)  
      Fall 49 (28.0%) 21 (32.3%)  
Ethnicity   0.029 
      Caucasian 117 (77.0%) 56 (93.3%)  
      Asian 6 (4.0%) 3 (5.0%)  
      African American / Black 23 (15.0%) 1 (1.7%)  
      Hispanic / Latino 3 (2.0%) 0 (0.0%)  
      Other 3 (2.0%) 0 (0.0%)   
* P value derived from two sample t test for continuous variables and from chi - square test for dichotomous or categorical variables. 
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Table 6. Distribution of covariates according to categorical 25-OH Vitamin D levels: Baystate vitamin D, 2008-2010 study (n = 
240). 
  25-OH Vitamin D  levels   
  Severe deficiency  Moderate  deficiency Insufficiency Normal p value* 
 N(%) N(%) N(%) N(%)  
n 42 (17.5%) 46 (19.2%) 87 (36.3%) 65 (27.1%)  
Age     0.025 
     2 to <10 years  1 (2.4%) 4 (8.7%) 18 (20.7%) 11 (16.9%)  
     10 to 21 years  41 (97.6%) 42 (91.3%) 69 (79.3%) 54 (83.1%)  
Sex     0.985 
     Male  20 (47.6%) 22 (47.8%) 39 (44.8%) 30 (46.2%)  
     Female 22 (52.4%) 24 (52.2%) 48 (55.2%) 35 (53.9%)  
BMI     <0.001 
     BMI < 19.8 (Underweight) 4 (9.5%) 5 (11.1%) 19 (22.1%) 11 (16.9%)  
     BMI 19.8 - 26.0 (Normal) 6 (14.3%) 11 (24.4%) 35 (40.7%) 28 (43.1%)  
     BMI > 26.0 - 29.0 (Overweight) 4 (9.5%) 6 (13.3%) 10 (11.6%) 9 (13.9%)  
     BMI ≥ 29.0 (Obese) 28 (66.7%) 23 (51.1%) 22 (25.6%) 17 (26.2%)  
BMIZ categorical     <0.001 
      BMIZ > 1.5 (Obese) 34 (81.0%) 30 (68.2%) 40 (46.5%) 28 (43.1%)  
      BMIZ ≤ 1.5 (Normal) 8 (19.1%) 14 (31.8%) 46 (53.5%) 37 (56.9%)  
Vitamin D supplementation     0.446 
      Yes 2 (4.7%) 0 (0.0%) 2 (2.3%) 3 (4.6%)  
      No 40 (95.2%) 46 (100.0%) 85 (97.7%) 62 (95.4%)  
Table 6 continued on next page.  
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Table 6 continued from previous page. Distribution of covariates according to categorical 25-OH Vitamin D levels: Baystate 
vitamin D, 2008-2010 study (n = 240). 
  25-OH Vitamin D  levels   
  Severe deficiency  Moderate  deficiency Insufficiency Normal p value* 
 N(%) N(%) N(%) N(%)  
Glycated hemoglobin (HbA1C)     0.209 
      HbA1C ≤ 8 (Acceptable) 22 (68.8%) 15 (45.5%) 48 (64.0%) 30 (57.7%)  
      HbA1C > 8 (Bad control) 10 (31.3%) 18 (54.6%) 27 (36.0%) 22 (42.3%)  
Seasons of  the year in US     0.343 
      Winter 8 (19.1%) 12 (26.1%) 14 (16.1%) 5 (7.7%)  
      Spring 10 (23.8%) 8 (17.4%) 15 (17.2%) 10 (15.4%)  
      Summer 12 (28.6%) 16 (34.8%) 31 (35.6%) 29 (44.6%)  
      Fall 12 (28.6%) 10 (21.7%) 27 (31.0%) 21 (32.3%)  
Ethnicity     0.013 
    Caucasian 23 (62.2%) 25 (71.3%) 69 (86.3 %) 56 (93.3%)  
    Asian 2 (5.4 %) 1 (2.9%) 3 (3.8%) 3 (5.0%)  
    African American / Black 9 (24.3%) 7 (20.0%) 7 (8.8%) 1 (1.7%)  
    Hispanic / Latino 2 (5.4%) 1 (2.9%) 0 (0.0%) 0 (0.0%)  
    Other 1 (2.7%) 1 (2.9%) 1 (1.3%) 0 (0.0%)  
 Mean (SD) Mean (SD) Mean (SD) Mean (SD)  
Age 15.26 (±2.87) 13.89 (±2.87) 13.29 (±4.00) 14.76 (±3.66) 0.01 
Weight 95.32 (±36.07) 80.51 (±30.78) 65.01 (±27.10) 68.01 (±22.29) <0.0001 
Height 163.20 (±12.46) 159.32 (±14.01) 154.99 (±18.09) 159.94 (±13.07) 0.0264 
BMIZ 4.42 (±15.06) 1.74 (±1.02) 1.45 (±1.09) 1.31 (±0.90) 0.0608 
Serum Calcium (Ca) 9.85 (±0.32) 9.90 (±0.39) 9.79 (±0.38) 9.70 (±0.48) 0.1268 
Glycated hemoglobin (HbA1C) 7.43 (±2.03) 8.51 (±2.69) 7.64 (±1.80) 7.84 (±1.47) 0.1137 
Parathyroid Hormone (PTH) 46.63 (±18.89) 37.91 (±12.60) 31.78 (±11.59) 31.95 (±8.70) <0.0001 
* P- value derived from ANOVA for continuous variables and from chi square test for dichotomous or categorical variables 
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Table 7. Distribution of covariates according to continuous 25-OH Vitamin D 
measures: Baystate vitamin D, 2008- 2010 study population (n=240). 
  25-OH Vitamin D continuous 
  Mean  SE p value* 
Age 
  
0.2131 
     2 to <10 years  26.70 1.18  
     10 to 21 years  24.32 0.75  
Sex 
  
0.766 
     Male  24.44 0.96  
     Female 24.84 0.92  
BMI 
  
0.0001 
     BMI < 19.8 (Underweight) 27.23 1.81  
     BMI 19.8 - 26.0 (Normal) 27.53 1.05  
     BMI > 26.0 - 29.0 (Overweight) 25.72 2.02  
     BMI ≥ 29.0 (Obese) 20.77 0.99  
BMIZ categorical 
  
<0.0001 
      BMIZ > 1.5 (Obese) 22.22 0.83  
      BMIZ ≤ 1.5 (Normal) 27.90 1.03  
Vitamin D supplementation 
  
0.6113 
      Yes 26.61 4.29  
      No 24.60 0.68  
Glycated hemoglobin (HbA1C) 
  
0.8744 
      HbA1C ≤ 8 (Acceptable) 25.20 1.05  
      HbA1C > 8 (Bad control) 24.95 1.07  
Seasons of  the year in US 
  
0.0066 
      Winter 20.58 1.33  
      Spring 22.88 1.30  
      Summer 27.02 1.28  
      Fall 25.03 1.11  
Ethnicity 
  
0.0001 
    Caucasian 26.12 0.75  
    Asian 26.23 3.76  
    African American / Black 17.14 1.49  
    Hispanic / Latino 13.13 3.23  
    Other 17.93 3.38  
* P value derived from ANOVA for continuous variables and from chi square test for dichotomous or 
categorical variables.         * a P value testing for statistical significance in trends.  
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Table 8. Distribution of continuous covariates according to continuous 25-OH Vitamin D measures: Baystate vitamin D 2008-  
2010 study (n = 240). 
  25-OH Vitamin D continuous 
  Pearson correlation (r)  p value* Spearman correlation (r)  p value* 
Age 0.03 0.6025a -0.01 0.9154 
Weight -0.27 <0.0001a -0.28 <0.0001 
Height -0.03 0.6542a -0.05 0.4734 
BMIZ -0.11 0.0917a -0.32 <0.0001 
Serum Calcium (Ca) -0.1 0.152a -0.1 0.1493 
Glycated hemoglobin (HbA1C) -0.03 0.7305a 0.04 0.5415 
Parathyroid Hormone (PTH) -0.31 <0.0001a -0.29 <0.0001 
* 
a
 P value testing for statistical significance in trends (Pearson's)   
*  P value testing for statistical significance in trends (Spearman's)   
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Table 9 for TC and TG.  Distribution of covariates according to dichotomous blood lipid levels: Baystate vitamin D 2008- 2010 
study population (n = 240). 
 Total Cholesterol (TC mg/dL) Triglyceride (TG mg/dL) 
  High Normal p value* High Normal p value* 
N 69 (28.8%) 146 (60.8%)  47 (19.6%) 120 (50.0%)  
Age   0.896   0.021 
   2 to <10 years  9 (13.0%) 20 (13.7%)  10 (21.3%) 10 (8.3%)  
  10 to 21 years  60 (87.0%) 126 (86.3%)  37 (78.7%) 110 (91.7%)  
Age 14.83 (3.60SD) 13.92 (3.51 SD) 0.0789 13.61 (3.84 SD) 14.52 (3.25 SD) 0.1218 
Sex   0.187   0.482 
   Male  26 (37.7%) 69(47.3%)  22 (46.8%) 49 (40.8%)  
   Female 43 (62.3%) 77 (52.7%)  25 (53.2%) 71 (59.2%)  
Weight 75.48 (32.57 SD) 72.70 (27.46 SD) 0.5149 84.99 (33.70 SD) 76.12 (27.82SD) 0.0835 
Height 158.78 (13.98 SD) 158.76 (15.40 SD) 0.996 157.67 (14.68 SD) 160.24 (13.67 SD) 0.2865 
BMI   0.847   0.024 
     BMI < 19.8 (Underweight) 10 (14.7%) 22 (15.1%)  2 (4.4%) 13 (10.8%)  
     BMI 19.8 - 26.0 (Normal) 24 (35.3%) 51 (34.9%)  8 (17.4%) 43 (35.8%)  
     BMI > 26.0 - 29.0 (Overweight) 7 (10.3%) 21 (14.4%)  7 (15.2%) 17 (14.2%)  
     BMI ≥ 29.0 (Obese) 27 (39.7%) 52 (35.6%)  29 (63.0%) 47 (39.2%)  
BMIZ 2.99 (11.93 SD) 1.59 (1.01 SD) 0.1599 4.31 (14.38 SD) 1.60 (1.00 SD) 0.0418 
BMIZ categorical   0.43   0.002 
      BMIZ > 1.5 (Obese) 35 (51.5%) 83 (57.2%)  38 (82.6%) 68 (57.1%)  
      BMIZ ≤ 1.5 (Normal) 33 (48.5% 62 (42.8%)  8 (17.4%) 51 (42.9%)  
Table 9. Continued on next page:   
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Table 9 for TC and TG. Continued from previous page:  Distribution of covariates according to dichotomous blood lipid 
levels: Baystate vitamin D 2008- 2010 study population (n = 240). 
 Total Cholesterol (TC mg/dL) Triglyceride (TG mg/dL) 
  High Normal 
p 
value* High Normal 
p 
value* 
Vitamin D supplementation   0.412   0.773 
      Yes 1 (1.5%) 5 (3.4%)  2 (4.3%) 4 (3.3%)  
      No 68 (98.6%) 141 (96.6%)  45 (95.7%) 116 (96.7%)  
Serum Calcium (Ca) 9.84 (0.39 SD) 9.77 (0.42 SD) 0.2644 9.84 (0.43 SD) 9.77 (0.44 SD) 0.393 
Glycated hemoglobin (HbA1C)   0.175   0.371 
      HbA1C ≤ 8 (Acceptable) 32 (55.2%) 75 (65.8%)  23 (76.7%) 64 (68.1%)  
      HbA1C > 8 (Bad control) 26 (44.8%) 39 (34.2%)  7 (23.3%) 30 (31.9%)  
Glycated hemoglobin (HbA1C) 8.35 (2.41 SD) 7.43 (1.68 SD) 0.004 6.81 (1.62 SD) 7.40 (1.82 SD) 0.1197 
Parathyroid Hormone (PTH) 35.46 (12.51 SD) 35.71 (14.38 SD) 0.9065 35.12 (17.67 SD) 37.22 (12.79 SD) 0.4219 
Seasons of  the year in US   0.151   0.484 
      Winter 10 (14.5%) 27 (18.5%)  9 (19.2%) 18 (15.0%)  
      Spring 9 (13.0%) 29 (19.9%)  6 (12.8%) 23 (19.2%)  
      Summer 24 (34.8%) 56 (38.4%)  17 (36.2%) 51 (42.5%)  
      Fall 26 (37.7%) 34 (23.3%)  15 (31.9%) 28 (23.3%)  
Ethnicity   0.418   0.044 
   Caucasian 50 (82.0%) 107 (83.0%)  38 (88.4%) 80 (76.9%)  
   Asian 4 (6.6%) 3 (2.3%)  1 (2.3%) 5 (4.8%)  
   African American / Black 7 (11.5%) 15 (11.6%)  2 (4.7%) 18 (17.3%)  
   Hispanic / Latino 0 (0.0%) 2 (1.6%)  2 (4.7%) 0 (0.0%)  
   Other 0(0.0%) 2 (1.6%)   0 (0.0%) 1 (1.0%)   
* P value derived from  two sample t test for continuous variables and from chi square test for dichotomous or categorical variables 
Table 9. Continued on next page:   
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Table 9 for HDL and LDL. Continued on next page:  Distribution of covariates according to dichotomous blood lipid levels: 
Baystate vitamin D 2008- 2010 study population (n = 240). 
 High Density Lipoprotein (HDL mg/dL) Low Density Lipoprotein (LDL mg/dL) 
  Low Sufficient 
p 
value* High Normal p value* 
n 51 (21.3%) 119 (49.6%)  16 (6.7%) 149 (62.1%)  
Age   0.603   0.449 
   2 to <10 years  5 (9.8%) 15 (12.6%)  1 (6.3%) 19 (12.8%)  
  10 to 21 years  46 (90.2%) 104 (87.4%)  15 (93.8%) 130 (87.3%)  
Age 13.88 (3.29 SD) 14.47 (3.49 SD) 0.3059 14.46 (3.60SD) 14.23 (3.45SD) 0.8026 
Sex   0.478   0.553 
   Male  24 (47.1%) 49 (41.2%)  8 (50.0%) 63 (42.3%)  
   Female 27 (52.9%)  70 (58.8%)  8 (50.0%) 86 (57.7%)  
Weight 92.75 (35.21SD) 71.89 (24.46SD) <0.0001 87.31 (38.16SD) 77.62 (28.80SD) 0.2177 
Height 159.54 (14.59 SD) 159.69 (13.58 SD) 0.9505 159.34 (13.14SD) 159.53 (14.18SD) 0.9576 
BMI   <0.001   0.401 
     BMI < 19.8 (Underweight) 1 (2.0%) 16 (13.6%)  0 (0.0%) 15 (10.1%)  
     BMI 19.8 - 26.0 (Normal) 8 (15.7%) 45 (38.1%)  4 (25.0%) 46 (31.1%)  
     BMI > 26.0 - 29.0 (Overweight) 6 (11.8%) 17 (14.4%)  2 (12.5%) 22 (14.9%)  
     BMI ≥ 29.0 (Obese) 36 (70.6%) 40 (33.9%)  10 (62.5%) 65 (43.9%)  
BMIZ 4.21 (13.79SD) 1.50 (1.01SD) 0.0346 2.05 (0.83SD) 2.40 (8.13SD) 0.8648 
BMIZ categorical   <0.001   0.352 
      BMIZ > 1.5 (Obese) 44 (88.0%) 61 (51.7%)  12 (75.0%) 93 (63.3%)  
      BMIZ ≤ 1.5 (Normal) 6 (12.0%) 57 (48.3%)  4 (25.0%) 54 (36.7%)  
Table 9 for HDL and LDL continued on next page: 
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Table 9. Continued from previous page for HDL and LDL : Distribution of covariates according to dichotomous blood lipid levels: 
Baystate vitamin D 2008- 2010 study population (n = 240). 
 High Density Lipoprotein (HDL mg/dL) Low Density Lipoprotein (LDL mg/dL) 
  Low Sufficient 
p 
value* High Normal p value* 
Vitamin D supplementation   0.856   0.557 
      Yes 2 (3.9%) 4 (3.4%)  1 (6.3%) 5 (3.4%)  
      No 49 (96.1%) 115 (96.6%)  15 (93.8%) 144 (96.6%)  
Serum Calcium (Ca) 9.81 (0.41SD) 9.79 (0.45SD) 0.7235 9.94 (0.42SD) 9.79 (0.44SD) 0.2902 
Glycated hemoglobin (HbA1C)   0.005   0.487 
      HbA1C ≤ 8 (Acceptable) 29 (87.9%) 58 (61.7%)  6 (60.0%) 79 (70.5%)  
      HbA1C > 8 (Bad control) 4 (12.1%) 36 (38.3%)  4 (40.0%) 33 (29.5%)  
Glycated hemoglobin (HbA1C) 6.26 (1.17SD) 7.65 (1.82SD) 0.0001 6.71 (1.52SD) 7.30 (1.82SD) 0.3242 
Parathyroid Hormone (PTH) 35.90 (14.25SD) 36.27 (13.60SD) 0.8833 38.27 (6.47SD) 36.70 (14.79SD) 0.7283 
Seasons of  the year in US   0.187   0.214 
      Winter 12 (23.5%) 16 (13.5%)  1 (6.3%) 26 (17.5%)  
      Spring 8 (15.7%) 20 (16.8%)  1 (6.3%) 27 (18.1%)  
      Summer 22 (43.1%) 46 (38.7%)  7 (43.8%) 60 (40.3%)  
      Fall 9 (17.7%) 37 (31.1%)  7 (43.8%) 36 (24.5%)  
Ethnicity   0.441   0.805 
   Caucasian 38 (86.4%) 83 (78.3%)  11 (78.6%) 105 (80.2%)  
   Asian 0 (0.0%) 6 (5.7%)  0 (0.0%) 6 (4.6%)  
   African American / Black 5 (11.4%) 15 (14.2%)  3 (21.4%) 17 (13.0%)  
   Hispanic / Latino 1 (2.3%) 1 (1.0%)  0 (0.0%) 2 (1.5%)  
   Other 0 (0.0%) 1 (1.0%)   0 (0.0%) 1 (0.8%)   
* P value derived from two sample t test for continuous variables and from chi square test for dichotomous or categorical variables 
  
61
 
Table 10. Pearson correlation of 25(OH)D and covariates with blood lipid levels: Baystate vitamin D, 2008- 2010 study 
population (n = 240). 
  
Total 
Cholesterol 
(TC mg/dL) 
Triglyceride (TG 
mg/dL) 
High Density 
Lipoprotein 
(HDL mg/dL) 
Low Density 
Lipoprotein 
(LDL mg/dL) 
  r p value* r p value* r p value* r p value* 
Vitamin D levels (vdl)  
-
0.18 0.0084 -0.21 0.006 0.22 0.0039 
-
0.17 0.0265 
Age 0.09 0.1978 -0.05 0.5221 0.28 0.0002 
-
0.02 0.7605 
Weight 
-
0.01 0.8804 0.22 0.0038 -0.35 <0.0001 0.01 0.8846 
Height 
-
0.05 0.4875 -0.07 0.3595 0.13 0.0805 
-
0.16 0.0424 
BMIZ 0.04 0.5921 0.32 <0.0001 -0.21 0.0074 0.02 0.8453 
Serum Calcium (Ca) 0.11 0.1315 0.05 0.5464 -0.12 0.1512 0.15 0.0852 
Glycated hemoglobin (HbA1C) 0.21 0.0049 -0.13 0.1575 0.43 <0.0001 -0.1 0.2947 
Parathyroid Hormone (PTH) 0.01 0.9128 -0.1 0.2355 -0.01 0.9391 0.13 0.1278 
* P value testing for statistical significance in trends 
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Table 11. Distribution of 25-OH Vitamin D  levels among blood lipid levels: Baystate vitamin D 2008- 2010 study (n = 240). 
  TC   TG   
 High Normal  High Normal  
  N % N % 
p-
value N % N % 
p-
value 
 25-OH vitamin D - dichotomized     0.39     0.057 
          <30.00 ng/ml    (Deficient) 53 76.8 104 71.2  39 83.0 82 68.3  
          ≥30.00 ng/ml    (Normal) 16 23.2 42 28.8  8 17.0 38 31.7  
        Total 69 100.0 146 100.0  47 100.0 120 100.0  
25-OH vitamin D - categories     0.402     0.089 
        < 15.00 ng/ml            (Severe deficiency ) 15 21.7 23 15.8  14 30 19 15.8  
       15.00 – 19.99 ng/ml   (Moderate  deficiency) 16 23.2 25 17.1  10 21.3 20 16.7  
       20.00 – 29.99 ng/ml   (Insufficiency) 22 31.9 56 38.4  15 31.9 43 35.8  
        ≥30.00 ng/ml             (Normal or Optimal) 16 23.2 42 28.8  8 17 38 31.7  
         Total 69 100.0 146 100.0  47 100.0 120 100.0  
 Mean SE Mean SE  Mean SE Mean SE  
25-OH Vitamin D - continuous (ng/ml) 22.97 1.30 25.39 0.85 0.1139 20.72 1.20 25.94 1.02 0.0041 
 Median Range Median Range  Median Range Median Range  
25-OH Vitamin D - continuous (ng/ml) 21 4.0 - 57.6 25 5.7 - 69.3   19.5 8.1 - 40.9 24.45 4.6 - 69.3   
* P - value derived from chi square test for dichotomous or categorical variables and from t test for continuous variables 
Table 11. Continued on next page for HDL and LDL 
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Table 11 continued from previous page for HDL and LDL. Distribution of 25-OH Vitamin D  levels among blood lipid 
levels: Baystate vitamin D 2008- 2010 study (n = 240). 
  HDL-C   LDL-C   
 Low Sufficient  High Normal  
  N % N % 
p-
value N % N % 
p-
value 
 25-OH vitamin D - dichotomized     0.01     0.391 
          <30.00 ng/ml    (Deficient) 44 86.3 80 67.2  13 81.3 106 71.1  
          ≥30.00 ng/ml    (Normal) 7 13.7 39 32.8  3 18.8 43 28.9  
        Total 51 100.0 119 100.0  16 100.0 149 100.0  
25-OH vitamin D - categories     0.005     0.418 
        < 15.00 ng/ml            (Severe deficiency ) 16 31.4 17 14.3  4 25.0 29 19.5  
       15.00 – 19.99 ng/ml   (Moderate  deficiency) 13 25.5 18 15.1  5 31.3 25 16.8  
       20.00 – 29.99 ng/ml   (Insufficiency) 15 29.4 45 37.8  4 25.0 52 34.9  
        ≥30.00 ng/ml             (Normal or Optimal) 7 13.7 39 32.8  3 18.8 43 28.9  
         Total 51 100.0 119 100.0  16 100.0 149 100.0  
           
 Mean SE Mean SE  Mean SE Mean SE  
25-OH Vitamin D - continuous (ng/ml) 20.92 1.25 25.96 1.00 0.0042 21.46 2.67 24.8 0.88 0.237 
 Median Range Median Range  Median Range Median Range  
25-OH Vitamin D - continuous (ng/ml) 18.7 11.0 - 46.4 25 4.6 - 69.3   18.5 6.7 - 45.9 23.3 4.6 - 69.3   
* P value derived from chi square test for dichotomous or categorical variables and from t test for continuous variables 
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Table 12. Odds Ratio of dyslipidemia by 25-OH Vitamin D levels: Bay State vitamin D 
study, 2008 -2010 (n = 240). 
  Cases Unadjusted  
P 
trend Multivariate  P trend 
 No. % OR 95% CI  OR 95% CI 
 
High Total Cholesterol (TC)         
   25-OH Vitamin D Normal 16 23.2 1 Referent 0.39 1 Referent 0.114 
   25-OH Vitamin D Deficient 53 76.8 1.34 0.69 - 2.60  1.95a 0.85 - 4.46  
         
  25-OH Vitamin D  Normal or Optimal 16 23.2 1 Referent 0.12 1 Referent 0.062 
  25-OH Vitamin D  Insufficiency 22 31.9 1.03 0.48 - 2.20  1.53a 0.62 - 3.83 
 
  25-OH Vitamin D Moderate  deficiency 16 23.2 1.68 0.72 - 3.94  2.90a 0.95 - 8.82 
 
  25-OH Vitamin D  Severe deficiency  15 21.7 1.71 0.72 - 4.08  2.41a 0.78 - 7.44  
         
   25-OH Vitamin D - continuous (Mean (SD)) 22.97 10.84 0.98 0.95 - 1.01 0.115 0.97 0.93 - 1.01 0.094 
High Triglyceride (TG)         
   25-OH Vitamin D Normal 8 17.0 1 Referent 0.061 1 Referent 0.231 
   25-OH Vitamin D Deficient 39 83.0 2.26 0.96 - 5.30  1.91b 0.66 - 5.47  
         
   25-OH Vitamin D  Normal or Optimal 8 17.0 1 Referent 0.012 1 Referent 0.006 
   25-OH Vitamin D  Insufficiency 15 31.9 1.66 0.63 - 4.34  1.03b 0.31 - 3.45  
   25-OH Vitamin D Moderate  deficiency 10 21.3 2.38 0.81 - 6.96  3.30b 0.74 - 14.81  
   25-OH Vitamin D  Severe deficiency  14 30.0 3.50 1.25 - 9.79  11.65b 1.93 - 70.27  
         
   25-OH Vitamin D - continuous (Mean (SD)) 20.72 8.20 0.95 0.91 - 0.98 0.005 0.91b 0.86 - 0.97 0.004 
Low High density Lipoprotein (HDL)         
   25-OH Vitamin D Normal 7 13.7 1 Referent 0.013 1 Referent 0.066 
   25-OH Vitamin D Deficient 44 86.3 3.06 1.27 - 7.42  2.51c 0.94 - 6.69  
         
   25-OH Vitamin D  Normal or Optimal 7 13.7 1 Referent 0.001 1 Referent 0.013 
   25-OH Vitamin D  Insufficiency 15 29.4 1.86 0.69 - 5.02  1.52c 0.50 - 4.56  
   25-OH Vitamin D Moderate  deficiency 13 25.5 4.02 1.37 - 11.79  5.06c 1.43 - 17.88  
   25-OH Vitamin D  Severe deficiency  16 31.4 5.24 1.83 - 15.06  3.56c 1.03 - 12.33  
         
   25-OH Vitamin D - continuous (Mean (SD)) 20.92 8.92 0.95 0.91 - 0.98 0.005 0.96c 0.92 - 1.00 0.062 
High Low density Lipoprotein (LDL)         
    25-OH Vitamin D Normal 3 18.8 1 Referent 0.397 1 Referent - 
    25-OH Vitamin D Deficient 13 81.3 1.76 0.48 - 6.48  - -  
         
    25-OH Vitamin D  Normal or Optimal 3 18.8 1 Referent 0.215 1 Referent - 
    25-OH Vitamin D  Insufficiency 4 25.0 1.10 0.23 - 5.20  - -  
    25-OH Vitamin D Moderate  deficiency 5 31.3 2.87 0.63 - 13.03  - -  
    25-OH Vitamin D  Severe deficiency  4 25.0 1.98 0.41 - 9.50  - -  
         
    25-OH Vitamin D - continuous (Mean (SD)) 21.46 10.67 0.97 0.92 - 1.02 0.236 - - - 
a adjusted for age, BMIZ  and HbA1C                   b adjusted for PTH, BMIZ and ethnicity               c adjusted for bmiz and ethnicity 
P value testing for trends                    * (-) due to lack of statistical power (small number of cases in each category), no covariates 
were found to be confounding the observed relationship 
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Table 13. Association between dyslipidemia by 25-OH Vitamin D levels: Baystate 
vitamin D study, 2008 -2010 (n=240). 
  
Regression 
coefficient 
Standard error 
(SE) P trend 
High Total Cholesterol (TC)    
        25-OH Vitamin D Normal 1 Referent 0.007 
        25-OH Vitamin D Deficient 14.82a 5.37  
    
        25-OH Vitamin D  Normal or Optimal 1 Referent 0.007 
        25-OH Vitamin D  Insufficiency 11.8a 5.78  
        25-OH Vitamin D Moderate  deficiency 21.75a 7.66  
        25-OH Vitamin D  Severe deficiency  17.68a 7.76  
    
        25-OH Vitamin D - continuous  -0.58a 0.25 0.022 
High Triglyceride (TG)    
        25-OH Vitamin D Normal 1 Referent 0.013 
        25-OH Vitamin D Deficient 30.91b 12.22  
    
        25-OH Vitamin D  Normal or Optimal 1 Referent 0.002 
        25-OH Vitamin D  Insufficiency 22.44b 13.06  
        25-OH Vitamin D Moderate  deficiency 41.07b 17.63  
        25-OH Vitamin D  Severe deficiency  56.30b 19.22  
        25-OH Vitamin D - continuous  -2.14b 0.59 <0.001 
Low High density Lipoprotein  (HDL)    
        25-OH Vitamin D Normal 1 Referent 0.188 
        25-OH Vitamin D Deficient -3.78c 2.85  
        25-OH Vitamin D  Normal or Optimal 1 Referent 0.005 
        25-OH Vitamin D  Insufficiency -0.61c 2.99  
        25-OH Vitamin D Moderate  deficiency -7.99c 4.00  
        25-OH Vitamin D  Severe deficiency  -9.67c 3.91  
        25-OH Vitamin D - continuous  0.37c 0.13 0.004 
High Low density Lipoprotein (LDL)    
        25-OH Vitamin D Normal 1 Referent 0.197 
        25-OH Vitamin D Deficient 6.57d 5.08  
        25-OH Vitamin D  Normal or Optimal 1 Referent 0.093 
        25-OH Vitamin D  Insufficiency 2.18d 5.83  
        25-OH Vitamin D Moderate  deficiency 13.35d 6.88  
        25-OH Vitamin D  Severe deficiency  8.11d 6.59  
        25-OH Vitamin D - continuous  -0.50d 0.21 0.019 
a
 Multivariate model includes: gender, glycated hemoglobin (HbA1C), ethnicity and season.  
b
 Multivariate model includes: bmiz, ethnicity and parathyroid hormone (PTH).  
c
 Multivariate model includes: age, gender, bmiz, glycated hemoglobin (HbA1C), ethnicity and season. 
d
 Multivariate model includes: age, height and season.  * P -  value testing for statistical significance in trend 
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